

OM protein - protein search, using sw model
 Run on: March 17, 2003, 08:44:13 ; Search time 42 seconds
 Copyright (c) 1993 - 2003 Compugen Ltd.

Pred. No. is the number of results predicted by chance to have a score greater than or equal to the score of the result being printed and is derived by analysis of the total score distribution.

SUMMARIES

Staphylococcus aur
Pseudomonas aerugi
E. coli cellular pro
Haemophilus influ
Salmonella typhi c
C glutamicum prote
Corynebacterium gl
Corynebacterium gl
Staphylococcus epi
Staphylococcus aur

84 301 7.4 639 21 AAY74438
 85 292 7.2 96 23 ABP08386
 86 284.5 7.0 21 AAG2764
 87 271 6.7 814 22 ABC19229
 88 264.5 6.5 120 22 AAG81451
 89 250 6.2 127 21 AAY28435
 90 239 5.9 119 19 AAW38591
 91 238 5.9 70 23 ABP04559
 92 212.5 5.2 268 18 AAW20584
 93 209 5.2 78 19 AAW79391
 94 209 5.2 263 21 AAY28441
 95 208.5 5.1 195 21 AAY28436
 96 207.5 5.1 533 23 ABB8994
 97 207 5.1 205 22 ABG05731
 98 204.5 5.0 553 22 AAB79520
 99 204.5 5.0 557 22 AAB79519
 100 198.5 4.9 203 18 AAW20430

ALIGNMENTS

RESULT 1

AAU34234

DT 14-FEB-2002

XX (first entry)

XX

XX Staphylococcus aureus cellular proliferation protein #510.

XX

XX Antisense; prokaryotic cellular proliferation protein;

XX

XX antibiotic; antibacterial; drug design.

XX

OS Staphylococcus aureus.

XX

PN WO200170955-A2.

XX

PD 27-SEP-2001.

XX

PF 21-MAR-2001; 2001WO-US09110.

XX

PR 21-MAR-2000; 2000US-191078P.

PR 23-MAY-2000; 2000US-206844P.

PR 26-MAY-2000; 2000US-20772P.

PR 23-OCT-2000; 2000US-242578P.

PR 27-NOV-2000; 2000US-25362P.

PR 22-DEC-2000; 2000US-257931P.

PR 16-FEB-2001; 2001US-269308P.

XX PA (ELIT) ELITRA PHARM INC.

XX PI Haselbeck R, Olsens KL, Zyskind JW, Wall D, Trawick JD, Carr GJ,

PI Yamamoto RT, Xu HH;

XX WPI; 2001-611495/70.

DR N-PSDE; AAS52033.

XX PT New polynucleotides for the identification and development of antibiotics, comprise sequences of antisense nucleic acids -

XX PS Example 3; Seq ID No 5730; 511bp; English.

The invention relates to antisense inhibitors of genes essential to prokaryotic cellular proliferation, their use in identifying the genes, their use in the discovery of novel antibiotics, the essential genes themselves and the encoded proteins. The prokaryotes used are, Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis. The invention is also useful for the identification of potential new targets for antibiotic development. The antisense nucleic acids can also be used to identify proteins used in proliferation, to express these proteins,

and to obtain antibodies capable of binding to the expressed proteins. The proteins can be used to screen compounds in rational drug discovery programmes. The antisense nucleic acid sequence is also useful to screen for homologous nucleic acids which are required for cell proliferation in a wide variety of organisms. The present sequence represents an essential prokaryotic cellular proliferation protein.

Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at [ftp.wipo.int/pub/published_pct_sequences](http://wipo.int/pub/published_pct_sequences).

SQ Sequence 644 AA;

Query Match 41.1%; Score 1666.5; DB 22; Length 644;

Best Local Similarity 48.7%; Pred. No. 2.3e-139; Mismatches 198; Index 81; Gaps 10;

Db 63 HNPVTI----D-FN-IKDEIAKQITLQKNAIDFGVHIFDGSDEQGIVHMGPETG 115

Qy 9 QTLYDKVLAHVVDEKLDTVLLYDRLHLVHEVTSQAFEGRLNAGRKVRPDTLATTD 68

Db 3 QTLFDKVNRRHVLGYKLGPQLYIDLHLIHEVTSQAFEGRLNQNKLRPDLTFTLTD 62

Qy 69 HNPVTTSRKALKDIASTFKEDDSRTQCYTLEENYKEFGTYFGLSDFDKGIVHVTGPEQG 128

Db 116 LTQFGKTVCGDSHTATHGAFGATAFGIGTSEVHVLATQCLITKRSKMR1QVGDGLFAP 188

Qy 129 FTLPGTTVYCGDSHTSTHGAFGALAFGIGTSEVHVLATQCLITKRSKMR1QVGDGLFAP 188

Db 129 9VSSKDVVLAHIGLTAGGTGAVIEFCVSVIRELUSMARMNSCMNSIEGARAGMVPD 248

Qy 189 GIVYAKDIIHLIILKTYGVDFGTGYALEFIGETIKNLSDGRMTICNMIAEGGAKYGIQPD 235

Db 176 GIVYAKDIIHLIILKTYGVDFGTGYALEFIGETIKNLSDGRMTICNMIAEGGAKYGIQPD 235

Qy 249 EITFEYLKGCRPLAKPQYDSDPWEHKAQVWQNLSQDPGAKYDIDVFTIDKDVPTLWGTSP 308

Db 236 DITFEYVGRPFAIDNF----AKSVDKRELYSDDDAIDFDRVIEDVSTLEPQVWGTNP 290

Qy 309 EDVYPITGVPDPETEATPAKKAQDGRMQLQYMGKLTGKATPMEDIPVYDGFVGSCTNRIED 368

Db 291 EMGYNFSEFP----BISDINDQRA7DYMGLBPGQRAEDIDIGYVFLGSCTNARLSD 343

Qy 369 LRAAAAYVKGKKAPAVNKSAMVPGSGLVKTQABEGGLKIPERAGFENREAGCSMCLGM 428

Db 344 LIEASHIYKGNKVPHPNI-TAIVYVGSRVTKREAKFGLDTIFKNAFENREP GCSMCLGM 402

Qy 429 NPDLAPQERCASTSNRNPFGROGAGGRTHLMSPVMAAGIVGKLADYVRLTDYKASPH 488

Db 403 NPDOVPEGYHCASTSNRNPFGROKKGARTHLVSPAMARAAAIIHGKFVDYRKV---- 454

Qy 489 IAYQKSTVTKPHYDERINODAHEKDTIADIPEDNNGPHNTNTSASVGTSAGLPKFTLKG 548

Db 455 -----VXXMKAIAKPTTYKG 469

Qy 549 IAPPLEKANVDTDAIIPKOFKLKTTKRTGLGNALFYEMRPNEDTEKSDFTVNLKNEPKAS 608

Db 470 KIVPLFENDNTDQIIPKVKHLKRISGFGPFADEWRYLPDGSIDNPDPNPKQYKGAS 529

Qy 609 ILVCTGANFGCGSSREHAFLPNDFGIRSVAIAPSFAIDFNNNSPKNGLPPIPKDQAQIE 668

Db 530 ILI-TGDNFGCGSSREHAFLWQYGFHIIAGSFSDIVMNCTKNAFDPIVLEKNAR-E 587

Qy 669 AIAAEARAGKEIWDLPNQLIKNTGGETICTFEVEFRKHCLVNGLDDIGLTMOMEDKIA 728

Db 588 HLAKVYV---EIEVDPNOTV--SSPDKSFHFEDETWNKLVNGLDDIAITLQYELIE 641

RESULT 2 AAU33631 standard; Protein; 474 AA.

ID AAU33631

AC	AAU33631;	QY	123 FTLGETTIVVCGDSHSSTHGFGAALFGIGSEVERVILATOCILITRSKKNRIOVQGELAP 18
XX	DT 14-FEB-2002 (first entry)	Db	123 ATPLGTMVTVCGDSHSSTHGFGAALFGIGSEVERVILATOCILITRSKKNRIOVQGELAP 18
XX	DE Pseudomonas aeruginosa cellular proliferation protein #75.	QY	189 GVSSDVKVHAIIGTGTAGGTGAVIIFCGSVIRTSMEARNISICNNSIEGGARAGMVPD 249 EITFEYLKGRLPLAKPKDSPEWPKHATQYKWHQIQLSDRCAKYDIDVIFIAKDTVPTLTWGTSP 300
XX	KW antibiotic; antibacterial; drug design.	Db	183 GVTAKDILAVIGRIGTAGGNGHAEFLFGSAIRDLISIEGRMTCINNSIEAARRGLVAVD 243 QKTDIVKGRIFFP--SAEQWQDQAVCWOGLVSADARDFTVELDAQIKRQVSMGTSP 309 EDVNPITGVVDPDETTATEAKKADGRMLQWMLKAGTPMPDIPVVKVFGSCTNSIED 360
OS Pseudomonas aeruginosa.	XX	QY	301 EMVLAQDQNPVDPDAPESDPTKRGTSERALKYLRPNQATIDQLDRVFIGSCTNSIED 361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
PR WO200170955-A2.	XX	Db	301 EMLVATDQNPVDPDAPESDPTKRGTSERALKYLRPNQATIDQLDRVFIGSCTNSIED 361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
PA (ELIT-) ELITRA PHARM INC.	XX	Db	301 EMLVATDQNPVDPDAPESDPTKRGTSERALKYLRPNQATIDQLDRVFIGSCTNSIED 361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
PA (ELIT-) ELITRA PHARM INC.	XX	QY	369 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
PI Haselbeck R, Ohlsen KU, Zyskind JW, Wall D, Trawick JD, Carr GJ;	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
PI Yamamoto RT, Xu HH;	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
PT WPI; 2001-611495/70.	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
PT N-PSDB; AAS31490.	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
PR Example 3; Seq ID No 5127; 51pp; English.	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
PR New polynucleotides for the identification and development of	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
PT antibiotics, comprise sequences of antisense nucleic acids -	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
PR Example 3; Seq ID No 5127; 51pp; English.	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC The invention relates to antisense inhibitors of genes essential to	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC prokaryotic cellular proliferation, their use in identifying the	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC genes, their use in the discovery of novel antibiotics, the essential	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC genes themselves and the encoded proteins. The prokaryotes used are	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis. The	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC invention is also useful for the identification of potential new targets	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC for antibiotic development. The antisense nucleic acids can also be used	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC to identify proteins used in proliferation, to express these proteins,	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC and to obtain antibodies capable of binding to the expressed proteins.	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC The proteins can be used to screen compounds in rational drug discovery	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC programmes. The antisense nucleic acid sequence is also useful to screen	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC for homologous nucleic acids which are required for cell proliferation in	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC a wide variety of organisms. The present sequence represents an	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC essential prokaryotic cellular proliferation protein.	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC Note: The sequence data for this patent did not form part	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC of the printed specification, but was obtained in electronic	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC format directly from WIPO at	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
CC ftp://wipo.int/pub/published_pct_sequences.	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
SQ Sequence 474 AA;	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX Query Match 37.2%; Score 1507.5; DB 22; Length 474;	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX Best Local Similarity 62.5%; Pred. No. 2.1e-125; Mismatches 295; Conservatv 61; Indels 3; Gaps 2;	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
QY 9 QTYLKDVKLQAHVVDKGLTGYLDRHLVHETVSPQAFEGLURNAGRKVRPPTCLTATD 68	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
Db 4 KTLKDVKLQAHVVDKGLTGYLDRHLVHETVSPQAFEGLURNAGRKVRPPTCLTATD 63	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
QY 69 HNVTTSKRALKDASPKEDDSRTOCVTLEVNKEFGVYFGLSDRKQGIVHVGPEQG 128	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
Db 64 HNVTTSKRALKDASPKEDDSRTOCVTLEVNKEFGVYFGLSDRKQGIVHVGPEQG 122	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX New polynucleotides for the identification and development of	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX antibiotics, comprise sequences of antisense nucleic acids -	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX Example 3; Seq ID No 10021; 51pp; English.	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX The invention relates to antisense inhibitors of genes essential to	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX prokaryotic cellular proliferation, their use in identifying the	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX genes, their use in the discovery of novel antibiotics, the essential	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX genes themselves and the encoded proteins. The prokaryotes used are	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis. The	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX invention is also useful for the identification of potential new targets	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX for antibiotic development. The antisense nucleic acids can also be used	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX to identify proteins used in proliferation, to express these proteins,	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX and to obtain antibodies capable of binding to the expressed proteins.	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX The proteins can be used to screen compounds in rational drug discovery	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX programmes. The antisense nucleic acid sequence is also useful to screen	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX for homologous nucleic acids which are required for cell proliferation in	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX a wide variety of organisms. The present sequence represents an	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX essential prokaryotic cellular proliferation protein.	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX Note: The sequence data for this patent did not form part	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX of the printed specification, but was obtained in electronic	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX format directly from WIPO at	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
XX ftp://wipo.int/pub/published_pct_sequences.	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472
SQ Sequence 474 AA;	XX	Db	361 LRAAAAVVKGRKKRPPKVKMSAMVPGSLVKVTOAEEGLDKIFEEAGFREWAGCSCMLGM 429 NPDILAPQERCASTSNRNFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 421 NPDRLSEGEHCASTSNNRFEGRQGAGGRTHLVPAMAAAATVNGRFIDVREL 472

CC invention is also useful for the identification of potential new targets
CC for antibiotic development. The antisense nucleic acids can also be used
CC to identify proteins used in proliferation, to express these proteins,
CC and to obtain antibodies capable of binding to the expressed proteins.
CC The proteins can be used to screen compounds in rational drug discovery
CC programmes. The antisense nucleic acid sequence is also useful to screen
CC for homologous nucleic acids which are required for cell proliferation in
CC a wide variety of organisms. The present sequence represents an
CC essential prokaryotic cellular proliferation protein.

CC Note: The sequence data for this Patent did not form part
CC of the printed specification, but was obtained in electronic
CC format directly from WIPO at
CC http://wipo.int/pubdb/published_pct_sequences.

Sequence	466 AA;	Score	1479.5;	DB	22;	Length	466;
Query	OTLYDKVLUQHVVDEBKLDGFTVLLYDRHLTHEVTSQAFPELNRNACRKVRPDCITLATTID 68	Best Local Similarity	62.1%;	Pred.	No. 6.6e-123;		
Matches	293;	Conservative	59;	Mismatches	111;	Indels	9;
Gaps							4;
Qy	69 HNVPTTSRALKDIAFSKIDDSRPTQCVLLENKVEFGFVYFGLSDRKRQGVHVGPEQG 128	Db	3 KTYLZEKLFDHVVYBAAENETPPLYLIDRHLTHEVTSQAFDGYLRAHSGPVRQPKTFATMD 62				
Qy	129 FTLPGTTVYCGDSHTSTHGAGFALAFGIGTSEVEHVLATOCLLITKRSKNNMRQYDGEELAP 188	Db	63 HNVSTQT ---KDINAC ---GEMARQMOELIKNCKEFGVLYDHLHPYQGLVHVMGPEQG 116				
Qy	117 VTPGPMTIVGDSHTATHGAGFALAFGIGTSEVEHVLATQTLKQGRAKTNIKIEVOSKAAP 176	Db	117 VTPGPMTIVGDSHTATHGAGFALAFGIGTSEVEHVLATQTLKQGRAKTNIKIEVOSKAAP 176				
Qy	189 GVSSKDVLHAIGIITGAGGTGAIEFCGGSVIRSLSMEEANSICMNSIEGGARAGKVAAPD 248	Db	177 GITADIVLIAIGKGSAGGTGHVYEFCGBAIRDLSMEGNTLICMAENGAKAGLVAPD 236				
Qy	249 EITPEYLKGRPLAKYDSDPBMHKATQYWNHLQSDGAKYIDVFLDAKDVPIVPTLWGTS P 308	Db	237 ETTEPVYVKRHLHAPK - GKFDAYAWKWLQTDGATFTVVTIQAEEISPOVTVWGTTNP 294				
Qy	309 EDVVPITGVVPDPETPFATEAKADGRMLQYMGFLRAGTPMDIPVYDKVFQGSCTINSRIED 368	Db	295 GOVISVNDNIPDPASFDAPVERASAEEKALYMGMLKPGIPIVTEAIDKVFQGSCTINSRIED 354				
Qy	369 LRAAAVWVKRGRKAKPNVKS3MVYPPSGLYTKQAAEPEGLDIFBEEAGFENWEGCSCMLGM 428	Db	355 LRAAAEIAKGRKVYAPGVQ - ULPVPGSGPYQAEEAEGLDKIFIEAGFENWLPGCSCLAM 413				
Qy	429 NPDILIAPOERCASTSNRNFGRQGAGGRTHLMSPTMAAAGIVGKLADYRKL 480	Db	414 NNDRLNPGERCCASTSNRNFGRQGAGGRTHLVSPTMAAAAVTGHFADIRNI 465				
RESULT 4							
AAU35571	AAU35571 standard; Protein; 469 AA.	XX					
AC		XX					
AAU35571;		XX					
14 - FEB-2002	(first entry)	XX					
Haemophilus	influenzae cellular proliferation protein #212.	XX					
Antisense;	prokaryotic cellular proliferation protein;	XX					
KW	antibiotic; antibacterial; drug design.	XX					
Haemophilus	influenzae.	XX					
WO00170955-A2.		XX					
21-MAR-2001; 2001WO-US09180.		XX					
PP		XX					
PD		XX					
27-SEP-2001.		XX					

XX 21-MAR-2000; 2000US-191078P.
 PR 23-MAY-2000; 2000US-20648P.
 PR 26-MAY-2000; 2000US-207727P.
 PR 23-OCT-2000; 2000US-242578P.
 PR 27-NOV-2000; 2000US-25365P.
 PR 12-DEC-2000; 2000US-257331P.
 PR 16-FEB-2001; 2001US-269308P.
 XX (ELIT-) ELITRA PHARM INC.
 PA Hasselbeck R,
 PA Ohlson KL,
 PI Zy HH,
 PI Yamamoto RT,
 PI Xu HH;

Best Local Similarity		60.6%	Pred.	No.	2.5e-120;
Matches	286;	Conservative	63;	Mismatches	114;
Indels	9;	Gaps	9;	Gaps	4;
QY	9	QTYDVKVHQAHVWDEKLQGTVLWYIDRHIVHEVTSQPAEFGIRNAGRKVRPDTCLATTD	429	NPDILAQERCASTSNRNFEGRQGAGGRTHLMSPVMAAAAGTVKLADVRKL	414
Db	3	KTYLEKLFDAHVVFEAPNETPLLYIDRHLVHEVSPQAOFGLRARRHRPVRQGKTFATMD	415	NDRIGEWECASTSNRNFEGRQGRNWRTHLVSAMAAAGVFGKFVDIRVT	467
QY	69	HNVFTTSRKALKOIASFIKEDDSITQCVILEENVKEFGVTVFGLSDKROGUVHVGPEQ	128	RESULT 5	
Db	63	HNVSTOT---KONA---SGMARIQMOELIKNENEFGVLYDNLNPYXGIVHVMGPEQX	116	AAU38424	
QY	129	FTLPGTTWVCGDHSITHGAFGALAFGIGTSEVENVLAOTCLIKRSKSNMFIQVDGELAP	188	AAU38424 standard; Protein; 466 AA.	
Db	117	VLPGMVKVCGDHSITAXHAGFAKGALXFGITSEVERVLAOTLKGRAKTMKIEVTGVAAP	176	14-FEB-2002 (first entry)	
QY	189	GYSSKDVTIHALGIGTAGGTGATIEFCVSIVRSLSMEARMSICMSIESGARAGMVAAP	248	Salmonella typhi cellular proliferation protein #315.	
Db	177	GITAKDIVLAIITGRTGSGAGTGHVFECDAAIRALSMEGRMTLCINMAIEMGAKAGLVAPD	236	Antisense; prokaryotic cellular proliferation protein;	
QY	249	ETTFEYUKGRPLAKYDSEPEWVKTOQYWKLUQSPGAKYIDVFDIADKIVTPTLWGTSP	308	antibiotic; antibacterial; drug design.	
Db	237	ETTFENYVYKGRHLAPK---GRDFDEBAVEWKLTDGATEFTVUTLRAEELAPQVWGTNP	294	Salmonella typhi.	
QY	309	EDVVPITGCVVPDDETFATBAKKADGRMRQYQMGKIKAGTPMEDIPIVDPKUVFQGSCTMRIED	368	W0200170955-A2.	
Db	295	GQVISVTDIIPDPSFSDPVERAASAKALAYMGQDQGPVPLTDVAIDKVFICSCINSRIED	354	PD 27-SEP-2001.	
QY	369	LRAAAVYVKGRKQAPAVNSAMVPGPSGLYKTOQAEEGLQKIFEEAGFENWBAGCSMCLGM	428	21-MAR-2001; 2001WO-US09180.	
Db	355	LRAAEVAKGRKVAPGVO-ALVWPGSPVKAQABEGLDKIFIEAGFENWBAGLPGCSMCLAM	413	23-MAY-2000; 2000US-206848P.	
QY	429	NEDILAQERCASTSNRNFEGRQGAGGRTHLMSPVMAAAAGTVKLADVRKL	480	26-MAY-2000; 2000US-207728P.	
Db	414	NNDRLNPGERCASTSNRNFEGRQGRRTHLVSAMAAAATVGHFADIRSI	465	27-OCT-2000; 2000US-242578P.	
PR	22-DEC-2000; 2000US-25731P.		27-NOV-2000; 2000US-253635P.		
PR	16-FEB-2001; 2001US-269308P.		16-FEB-2001; 2001US-269308P.		
PA	(ELIT-) ELITRA PHARM INC.				
PK	Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GJ;				
PI	Yamamoto RT, Xu HH;				
PX	WPI; 2001-611495/70.				
PR	N-PSDB; AAS56283.				
PS	New polynucleotides for the identification and development of antibiotics, comprise sequences of antisense nucleic acids - Example 3; Seq ID No 14017; 51PP; English.				
PT	The invention relates to antisense inhibitors of genes essential to prokaryotic cellular proliferation, their use in identifying the genes, their use in the discovery of novel antibiotics, the essential genes themselves and the encoded proteins. The prokaryotes used are Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis. The invention is also useful for the identification of potential new targets for antibiotic development. The antisense nucleic acids can also be used to identify proteins used in proliferation, to express these proteins, and to obtain antibodies capable of binding to the expressed proteins. The proteins can be used to screen compounds in rational drug discovery programmes. The antisense nucleic acid sequence is also useful to screen for homologous nucleic acids which are required for cell proliferation in a wide variety of organisms. The present sequence represents an essential prokaryotic cellular proliferation protein.				
CC	Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences.				
CC	Sequence 466 AA;				
CC	35.8%; Score 1450.5; DB 22; Length 466;				
CC	Query Match				

Claim 17; SEQ ID NO: 4952; 246pp + Sequence Listing; English.									
The present invention provides a number of nucleotide and protein sequences from the Coryneform bacterium Corynebacterium glutamicum. These are useful for identifying the mutation point of a gene derived from a mutant of coryneform bacterium, measuring expression amount and analysing the expression profile or expression pattern of a gene derived from Coryneform bacterium, and identifying a homologue of a gene derived from coryneform bacterium. Coryneform bacteria are useful for producing amino acids, nucleic acids, vitamins, saccharides and organic acids, particularly lysine. The present sequence is a protein described in the exemplification of the invention.									
Note: The sequence data for this patent did not form part of the printed specification, but was obtained in electronic format directly from the European Patent Office.									
Sequence 481 AA;									
Query Match 33.2%; Score 1347.5; DB 22; Length 481; Best Local Similarity 57.6%; Pred. No. 4.1e-111; Mismatches 61; Indels 13; Gaps 6									
Matches 273; Conservative 61; MisMatches 127; Indels 13; Gaps 6									
10 TLYDKVQAHVYDEKLGDGTW-LIVYDPRHLVHEVTSPOAEGEURNAGRKVRREDCUTLATTD 68									
15 "TLLAEKWRDHYVSKGENGEPDLLYDILQLQHBEVTSPOAEGEURNAGRKVRREDCUTLATTD 74									
19 HNVPTTSRALKDIAPIKEDD--SETQCVTLEENVKFEGTYFGSLSDKRQGIVHVGPE 126									
24 "TLLAEKWRDHYVSKGENGEPDLLYDILQLQHBEVTSPOAEGEURNAGRKVRREDCUTLATTD 74									
29 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
34 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
39 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
44 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
49 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
54 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
59 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
64 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
69 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
74 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
79 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
84 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
89 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
94 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
99 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
104 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
109 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
114 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
119 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
124 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
129 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
134 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
139 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
144 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
149 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
154 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
159 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
164 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
169 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
174 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
179 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
184 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
189 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
194 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
199 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
204 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
209 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
214 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
219 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
224 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
229 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
234 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
239 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
244 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
249 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
254 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
259 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
264 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
269 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
274 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
279 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
284 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
289 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
294 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
299 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
304 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
309 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
314 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
319 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
324 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
329 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
334 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
339 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
344 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
349 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
354 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
359 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
364 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
369 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
374 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
379 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
384 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
389 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
394 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
399 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
404 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
409 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
414 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
419 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									
424 75 HNVPIEGTK --GSILEETNDKISLQLQVSTLRDNEEFYQLRHPMGDVYRGIVVYPO 130									

PT Nucleic acids from *Corynebacterium glutamicum* encoding metabolic
PT pathway proteins, useful for producing fine chemicals in
PT microorganisms, including organic acids, nonproteinogenic amino acids,
PT and purine and pyrimidine bases -

XX AAF71753 to AAF72330 encode the *Corynebacterium glutamicum* metabolic
CC pathway (MP) proteins given in AAB79634 to AAB80211. The *C. glutamicum*
CC MP nucleic acids are useful for the production of fine chemicals
in microorganisms, including organic acids, nonproteinogenic amino
CC acids, purine and pyrimidine bases, nucleosides, nucleotides, lipids,
CC saturated and unsaturated fatty acids, diols, carbohydrates, aromatic
CC compounds, vitamins, cofactors, polyketides and enzymes.
XX

SQ Sequence 553 AA;

Query Match 32.8%; Score 1330; DB 22; Length 553;
Best Local Similarity 57.9%; Pred. No. 1. 9e-09; Matches 267; Conservative 60; Mismatches 124; Indels 10; Gaps 5;

QY 10 TLYDKVLOAKHVDKLDGTV-LLYIDRHLVHEVTSPOAFEGLNAGRKRVRDPDTLATT 68
|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:
Db 15 TLANKWWRHVKENGEDPLLYIDLQLLHEVTSQAFDGLRMTGRKLREPHELTED 74

QY 127 QGFILPGTIVVCGHSHTSITGAGALAFGICSEVHVLATOCILTKRSKMRQIQLDGL 186
|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:
Db 131 LGATOPGMNTIVCGPSHTSTHGAFGMAFGIGTSEVHVMATQPLPKPKM 190
|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:
QY 187 APGVSQKDVVHLAIGIGTAGGTGAVIEFCOSVSIISLMEARMSICNMSTEGGAGMVA 246
|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:
Db 191 QPGYSSKDDILAIIAKIGTGGQQGVLYERGEAIIKMSIDARMTKCNMSIABAGAGMIA 250
|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:
QY 247 PDEITFEXYIKGRPLAKPQVSPPEWKATQYQWNLQNSDPGAKYDIDVFDKADQIVPTLTWT 306
|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:
Db 251 PDQTTFDYVEGRENAPK- -GADWDEAVAYWKTLPTEGATEFDKVVEIDGSALTPTWTG 308
|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:
QY 307 SPEDVVPITGVVPPPETFTEAKKADGRRLQYQMGKAGPMDPFDVKVPIGSCINSRI 366
|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:
Db 309 NGPGQGULPQESVSPEDFTNDKAAEKAQYOMDILVPGTPLRDKIDTVFLGSCINARI 368
|||:|||:|||:|||:|||:|||:|||:|||:|||:
QY 367 EDLRAAAAVVKGRKKPAVNKSAMVPGPSLVKTOAEEGDKIFEEAGFENREAGCSMCL 426
|||:|||:|||:|||:|||:|||:|||:|||:
Db 369 EDLQIAADILKGHKIADGIR-MMVPSSTWIKQEAEALGLKIFDAGAERTAGCSMCL 427
|||:|||:|||:|||:|||:|||:|||:|||:
QY 427 GMNDILAPQERCASTSNHNFEGROGAGGRTHLMSPVMAA 467
|||:|||:|||:|||:|||:|||:|||:
Db 428 GMNPDQKPGERSAFTSNHNFEGRQGPGRTHLVSPPAVAA 468
|||:|||:|||:|||:|||:|||:
RESULT 8
AAB7967
ID AAB79767 standard; Protein; 534 AA.
XX
AC AAB79767;
XX
DT 30-APR-2001 (first entry)
XX
DE Corynebacterium glutamicum MP protein sequence SEQ ID NO:268.
XX
KW Corynebacterium glutamicum; metabolic pathway protein; MP protein;
KW fine chemical production; microorganism; organic acid; nucleoside;
KW nonproteinogenic amino acid; purine base; pyrimidine base; nucleotide;
KW lipid; saturated fatty acid; unsaturated fatty acid; diol; vitamin;
KW carbohydrate; aromatic compound; cofactor; polyketide; enzyme.
XX
OS Corynebacterium glutamicum.
XX
PN WO200100843-A2.
XX

XX Pompejus M, Kroeger B, Schroeder H, Zeider O, Haberhauer G;
XX WII; 2001-137957/14.
DR DR N-FPSDB; AAF71886.
XX
PT Nucleic acids from *Corynebacterium glutamicum* encoding metabolic
PT pathway proteins, useful for producing fine chemicals in

XX PR 04-JAN-2001.
PD 04-JAN-2001.
XX 23-JUN-2000; 2000WO-IB00923.
PF 25-JUN-1999; 99US-0141031.
PR 01-JUL-1999; 99DB-1030476.
PR 02-JUL-1999; 99US-0142101.
PR 08-JUL-1999; 99DB-1031415.
PR 08-JUL-1999; 99DB-1031416.
PR 08-JUL-1999; 99DB-1031419.
PR 08-JUL-1999; 99DB-1031420.
PR 08-JUL-1999; 99DB-1031424.
PR 08-JUL-1999; 99DB-1031428.
PR 08-JUL-1999; 99DB-1031434.
PR 08-JUL-1999; 99DB-1031435.
PR 08-JUL-1999; 99DB-1031453.
PR 08-JUL-1999; 99DB-1031457.
PR 08-JUL-1999; 99DB-1031465.
PR 08-JUL-1999; 99DB-1031478.
PR 08-JUL-1999; 99DB-1031510.
PR 08-JUL-1999; 99DB-1031541.
PR 08-JUL-1999; 99DB-1031573.
PR 08-JUL-1999; 99DB-1031592.
PR 08-JUL-1999; 99DB-1031632.
PR 08-JUL-1999; 99DB-1031634.
PR 08-JUL-1999; 99DB-1031636.
PR 09-JUL-1999; 99DB-1032125.
PR 09-JUL-1999; 99DB-1032126.
PR 09-JUL-1999; 99DB-1032130.
PR 09-JUL-1999; 99DB-1032186.
PR 09-JUL-1999; 99DB-1032206.
PR 09-JUL-1999; 99DB-1032227.
PR 09-JUL-1999; 99DB-103228.
PR 09-JUL-1999; 99DB-103228.
PR 09-JUL-1999; 99DB-103229.
PR 09-JUL-1999; 99DB-103230.
PR 14-JUL-1999; 99DB-103292.
PR 14-JUL-1999; 99DB-1032928.
PR 14-JUL-1999; 99DB-103304.
PR 14-JUL-1999; 99DB-103305.
PR 14-JUL-1999; 99DB-103306.
PR 12-AUG-1999; 99US-0148613.
PR 27-AUG-1999; 99DB-1040764.
PR 27-AUG-1999; 99DB-1040765.
PR 27-AUG-1999; 99DB-1040766.
PR 27-AUG-1999; 99DB-1040832.
PR 31-AUG-1999; 99DB-1041378.
PR 31-AUG-1999; 99DB-1041379.
PR 31-AUG-1999; 99DB-1041380.
PR 31-AUG-1999; 99DB-1041394.
PR 31-AUG-1999; 99DB-1041395.
PR 03-SEP-1999; 99DB-1042076.
PR 03-SEP-1999; 99DB-1042077.
PR 03-SEP-1999; 99DB-1042086.
PR 03-SEP-1999; 99DB-1042087.
PR 03-SEP-1999; 99DB-1042088.
PR 03-SEP-1999; 99DB-1042095.
PR 03-SEP-1999; 99DB-1042124.
PR 03-SEP-1999; 99DB-1042129.
PR 03-MAR-2000; 2000US-0187970.
XX
PA (BADI) BASF AG.
XX
PA Pompejus M, Kroeger B, Schroeder H, Zeider O, Haberhauer G;
XX WII; 2001-137957/14.
DR DR N-FPSDB; AAF71886.
XX
PT Nucleic acids from *Corynebacterium glutamicum* encoding metabolic

XX DE Staphylococcus aureus cellular proliferation protein #733.
 XX KW Antisense; prokaryotic cellular proliferation protein;
 XX antibiotic; antibacterial; drug design.
 XX OS Staphylococcus aureus.
 XX WO200170955-A2.
 XX PD 27-SEP-2001.
 XX PR 21-MAR-2001; 2001WO-US09180.
 XX PR 21-MAR-2000; 2000US-191078P.
 XX PR 23-MAY-2000; 2000US-206848P.
 XX PR 23-MAY-2000; 2000US-207727P.
 XX PR 23-OCT-2000; 2000US-242588P.
 XX PR 27-NOV-2000; 2000US-253625P.
 XX PR 22-DEC-2000; 2000US-257931P.
 XX PR 16-FEB-2001; 2001US-269308P.
 PA (ELIT-) ELITRA PHARM INC.
 XX AAU7335 standard; Protein; 456 AA.
 PI Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GJ;
 XX AC Xu HH;
 DR WPI: 2001-611495/70.
 DR N-PSDB; AAS54422.
 XX PT New polynucleotides for the identification and development of
 PT antibiotics, comprise sequences of antisense nucleic acids -
 PS Example 3; Seq ID No 12156; 51pp; English.
 XX
 CC The invention relates to antisense inhibitors of genes essential to
 CC prokaryotic cellular proliferation, their use in identifying the
 CC genes, their use in the discovery of novel antibiotics, the essential
 CC genes themselves and the encoded proteins. The prokaryotes used are
 CC Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella
 CC pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis. The
 CC invention is also useful for the identification of potential new targets
 CC for antibiotic development. The antisense nucleic acids can also be used
 CC to identify proteins used in proliferation, to express these proteins,
 CC and to obtain antibodies capable of binding to the expressed proteins.
 CC The proteins can be used to screen compounds in rational drug discovery
 CC programmes. The antisense nucleic acid sequence is also useful to screen
 CC for homologous nucleic acids which are required for cell proliferation in
 CC a wide variety of organisms. The present sequence represents an
 CC essential prokaryotic cellular proliferation protein.
 CC Note: The sequence data for this patent did not form part
 CC of the printed specification, but was obtained in electronic
 CC format directly from WIPO at
 CC ftp.wipo.int/pub/published/pct/ sequences.
 XX Sequence 456 AA;
 CC Query Match 31.6%; Score 1282; DB 22; Length 456;
 CC Best Local Similarity 54.4%; Pred. No. 2; 6e-105;
 CC Matches 257; Conservative 64; Mismatches 131; Indels 20; Gaps 5;
 CC OS AAU7335 standard; Protein; 456 AA.
 CC PN 189 GVSSKDVVVAHAGTTGTAGCTGATVTEFCSESVIRISMEAMSTCIMSIESTGARAGNAPD 248
 CC DB 176 GNVAKDIDILHLIKIYGVDFTGTYALEFTGETIKNSMDGRMTICNMAIEGGAKYGYIOPD 235
 CC QY 249 EITEYKLKRPLAKYDSPEWHKATQYWNLQSQPGAKYIDVFDKDIDVPTLWGTPSP 308
 CC DB 236 DITFVYKGRPFADNF----AKSVKWRBLYSDDAIFDRVILDVLDVSTLBPOVWTGTP 290
 CC QY 309 EDVTPITGVVPDPFETFATKAKDGRMLOYMGKAGTPMEDIPIVDKVFQGSCNTNSRIED 368
 CC DB 291 EMGVNFSEPP-----EISDINDORAVDYMGLERPGQKAEIDLGYVFLGSCNTWRLSD 343
 CC QY 369 LRAIAAVVKGKPKAPNUKSVAMVWVSGSLVKTQAEGLDKPFEAGFENWBAQCSNCCLGM 428
 CC DB 344 LIEASHIVKGNKVHPI-TAIVVPSRTVREAKEKLGLDTIFKNAFGEWREPGCSNCCLGM 402
 CC QY 429 NPDPLAQPOERCASSTSNRNFEGRQGAGGRTHLMSPUMAAAGIIVGKLADEVKL 480
 CC DB 403 NPDOVPEGVHCASTSNRNFEGRQGKARTHILVSPAMAAAIAHGKFDVDRKV 454
 PA (ELIT-) ELITRA PHARM INC.
 XX AAU7335 standard; Protein; 456 AA.
 PI Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GJ;
 XX AC Xu HH;
 DR WPI: 2001-611495/70.
 DR N-PSDB; AAS54422.
 XX PT New polynucleotides for the identification and development of
 PT antibiotics, comprise sequences of antisense nucleic acids -
 PS Example 3; Seq ID No 12156; 51pp; English.
 XX
 CC The invention relates to antisense inhibitors of genes essential to
 CC prokaryotic cellular proliferation, their use in identifying the
 CC genes, their use in the discovery of novel antibiotics, the essential
 CC genes themselves and the encoded proteins. The prokaryotes used are
 CC Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella
 CC pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis. The
 CC invention is also useful for the identification of potential new targets
 CC for antibiotic development. The antisense nucleic acids can also be used
 CC to identify proteins used in proliferation, to express these proteins,
 CC and to obtain antibodies capable of binding to the expressed proteins.
 CC The proteins can be used to screen compounds in rational drug discovery
 CC programmes. The antisense nucleic acid sequence is also useful to screen
 CC for homologous nucleic acids which are required for cell proliferation in
 CC a wide variety of organisms. The present sequence represents an
 CC essential prokaryotic cellular proliferation protein.
 CC Note: The sequence data for this patent did not form part
 CC of the printed specification, but was obtained in electronic
 CC format directly from WIPO at
 CC ftp.wipo.int/pub/published/pct/ sequences.
 XX Sequence 456 AA;
 CC Query Match 31.6%; Score 1282; DB 22; Length 456;
 CC Best Local Similarity 54.4%; Pred. No. 2; 6e-105;
 CC Matches 257; Conservative 64; Mismatches 131; Indels 20; Gaps 5;
 CC OS AAU7335 standard; Protein; 456 AA.
 CC PN 189 GVSSKDVVVAHAGTTGTAGCTGATVTEFCSESVIRISMEAMSTCIMSIESTGARAGNAPD 248
 CC DB 176 GNVAKDIDILHLIKIYGVDFTGTYALEFTGETIKNSMDGRMTICNMAIEGGAKYGYIOPD 235
 CC QY 249 EITEYKLKRPLAKYDSPEWHKATQYWNLQSQPGAKYIDVFDKDIDVPTLWGTPSP 308
 CC DB 236 DITFVYKGRPFADNF----AKSVKWRBLYSDDAIFDRVILDVLDVSTLBPOVWTGTP 290
 CC QY 309 EDVTPITGVVPDPFETFATKAKDGRMLOYMGKAGTPMEDIPIVDKVFQGSCNTNSRIED 368
 CC DB 291 EMGVNFSEPP-----EISDINDORAVDYMGLERPGQKAEIDLGYVFLGSCNTWRLSD 343
 CC QY 369 LRAIAAVVKGKPKAPNUKSVAMVWVSGSLVKTQAEGLDKPFEAGFENWBAQCSNCCLGM 428
 CC DB 344 LIEASHIVKGNKVHPI-TAIVVPSRTVREAKEKLGLDTIFKNAFGEWREPGCSNCCLGM 402
 CC QY 429 NPDPLAQPOERCASSTSNRNFEGRQGAGGRTHLMSPUMAAAGIIVGKLADEVKL 480
 CC DB 403 NPDOVPEGVHCASTSNRNFEGRQGKARTHILVSPAMAAAIAHGKFDVDRKV 454
 PA (ELIT-) ELITRA PHARM INC.
 XX AAU7335 standard; Protein; 456 AA.
 PI Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GJ;
 XX AC Xu HH;
 DR WPI: 2001-611495/70.
 DR N-PSDB; AAS54422.
 XX PT New polynucleotides for the identification and development of
 PT antibiotics, comprise sequences of antisense nucleic acids -
 PS Example 3; Seq ID No 12928; 51pp; English.
 XX
 CC The invention relates to antisense inhibitors of genes essential to
 CC prokaryotic cellular proliferation, their use in identifying the
 CC genes, their use in the discovery of novel antibiotics, the essential
 CC genes themselves and the encoded proteins. The prokaryotes used are
 CC Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella
 CC pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis. The
 CC invention is also useful for the identification of potential new targets
 CC for antibiotic development. The antisense nucleic acids can also be used
 CC to identify proteins used in proliferation, to express these proteins,
 CC and to obtain antibodies capable of binding to the expressed proteins.

CC The proteins can be used to screen compounds in rational drug discovery
 CC programmes. The antisense nucleic acid sequence is also useful to screen
 CC for homologous nucleic acids which are required for cell proliferation in
 CC a wide variety of organisms. The present sequence represents an
 CC essential prokaryotic cellular proliferation protein.
 CC Note: The sequence data for this patent did not form part
 CC of the printed specification, but was obtained in electronic
 CC format directly from WIPO at
 CC ftp://wipo.int/pub/published_pct_sequences.

XX Sequence 456 AA:
 XX Query Match 31.6%; Score 1282; DB 22; Length 456;
 XX Best Local Similarity 54.8%; Pred. No. 2.6e-15; Indels 5;
 XX Matches 257; Conservative 64; Mismatches 131; Gaps 5;
 XX
 Qy 9 QTLDKVLOAHVDEKLDGTVLILYDRHLVBEVTSPQAPEGLNRAGKVRPDCMTATTD 68
 Db 3 QTLDFKVNHRVLYKLGEPEPOLYIDHLHLEHTSPQAPEGLNLQRKLRPDLTPATLD 62
 XX
 Qy 69 HNVPTTSRKALKDIAFSIKEYDSRTQCVTLEENVKEFGTVTFLSDERGQVHVGSEQ 128
 Db 63 HNVPTI----DIFN-IKDTEANKQTTLRQNAIDGVHIFDGMGSDEQGIVHVMGPETG 115
 XX
 Qy 129 FTLPGTTVVGCGDSHTSTHGAGFALAFGIGTSEVEHVLATOCLLIKRSKNMRIQVDGELAP 188
 Db 116 LTQPGKTTIVCCDSHTATHGAGIAFGIGTSEVEHVFATQTLWQTKPNLIDINGLPT 175
 XX
 Qy 189 GVSXKDVLHLAIGIIGTAGGGAVIPEGSVTIRLSMEARNSICMNSIEGGARAGMVAPD 248
 Db 176 GVVARDILHLIKTYGVDFGTYGALLEFTGETIKNLSDGMTRICNMMAIEGAKYGIQD 235
 XX
 Qy 249 EITFEYLKGRLDAPKIDSPPEWHTKATQWKNLQSDPEGAKYDIDFIDARDIVTLLTGTP 308
 Db 236 DITFEVKGRAFDNF----AKSVDKWRELYSDDDAIFDRYIELDVSTLEPQVITGTPN 290
 XX
 Qy 309 EDVVPITGTVVDPDPETATEAKKADGRMRMLQYNGLKAGTGPMDIPDVDKVFIGCTNSRIED 368
 Db 291 EMGVNFSSEPFP-----EINDINDQRAYDINGLEPQKAEDIDLGVFLGSGCTNARLSD 343
 XX
 Qy 369 LRAAAAVVKGRKKAPVNVKSAWNVPGSLVKTOAEEGLDKTPEEAPEGEWREPGCSMCLGM 428
 Db 344 LIEASHIVKGKVKHPNIT-TAIVPGSRTVKREAELQGKDTLFKNGAEPEWPCCSMCLGM 402
 XX
 Qy 429 NPDILAPQERCAASTSIRNFBERQGAGERTHIMSPWMAAAAGTVGKLAADVRL 480
 Db 403 NPDQVPEGVHCASTSRRNFBERQGKGAARTHIVSPWMAAAATHGKFDVVRV 454

RESULT 12
 ID ABB48172 standard; Protein: 462 AA.
 XX
 AC ABB48172;
 XX DT 05-FEB-2002 (first entry)
 OS Listeria monocytogenes.
 XX DE Listeria monocytogenes protein #876.
 XX
 KW Antibacterial; Gene therapy; vaccine; biosynthesis; biodegradation;
 KW vitamin B12; bacterial infection; disease.
 XX
 Qy 309 EDVVPITGTVVDPDPETATEAKKADGRMLQYNGLKAGTGPMDIPDVDKVFIGCTNSRIED 368
 Db 292 EMGVFSSKAFP----EIKDMNMYERAYEVMGLKPGQTAEQIELGYVFIGSCTNARLSD 344
 XX
 Qy 369 LRAAAAVVKGRKKAPVNVKSAWNVPGSLVKTOAEEGLDKTPEEAPEGEWREPGCSMCLGM 428
 Db 345 LEEARAVVGKVKNNR-ALVPPSRQVNAAESIGLDKIFIEAFWREPGCSMCLGM 403
 PA (INSP) INST PASTEUR.

XX Buchrieser C, Frangeul L, Couve E, Rusniok C, Fsihi H, Dehoux P;
 PI Dusserget O, Chehouani F, Nedjari H, Glaser P, Kunst F, Cossart P;
 PI Daniels J, Goebel W, Kreft J, Kuhn M, Ng E, Vazquez-Boland JA;
 PI Dominguez-Bernal G, Garrido-Garcia P, Tierrez-Martinez A, Amend A;
 PI Chakraborty T, Domann E, Hain T, Borch C, Charbit A, Durant L;
 PI Perez-Diaz J, Baguero F, Garcia Del Portillo F, Gomez-Lopez N;
 PI Madueno E, De Pablos B, Wehland J, Kaerst U, Entian K, Hauf J;
 PI Rose M, Voss H;
 XX WPI; 2002-010914/01.
 XX DR
 XX PT
 PT PT
 PT PT
 PT PT
 XX
 PS SEQ ID No 877; 192DP; French.
 XX
 CC The present invention relates to the genome sequence of *Listeria*
 CC monocytogenes EGD-e (see ABA03041). The genome sequence and fragments of
 CC monocytes and primers for detecting genes in *L.*
 CC monocytes and related organisms, and for studying genetic
 CC polymorphisms and other genomes. The present sequence is a protein
 CC encoded by the genome sequence of the present invention. Proteins
 CC expressed from the genome sequence are useful for raising specific
 CC antibodies, identification of *L.* monocytogenes and related organisms, and
 CC for biosynthesis and biodegradation, especially biosynthesis of Vitamin
 CC B12. The genome sequence and proteins encoded by it are also useful for
 CC selecting compounds that regulate gene expression and cell replication
 CC and modulate *L.* monocytogenes-related diseases. In addition, the genome
 CC sequence and proteins encoded by it are useful in pharmaceutical and
 CC vaccines compositions for the treatment or prevention of infections by *L.*
 CC monocytes and related organisms.
 CC Note: The sequence data for this patent did not form part of the printed
 CC specification, but was obtained in electronic format directly from WIPO
 CC at ftp://wipo.int/pub/published_pct_sequences.
 XX
 SQ Sequence 462 AA;
 XX
 Query Match 31.6%; Score 1279.5; DB 23; Length 462;
 Best Local Similarity 53.8%; Pred. No. 4.5e-105;
 Matches 65; Mismatches 134; Indels 19; Gaps 4;
 Matches 25;
 XX
 Qy 9 QTLYDKVLOAHVDEKLDGTVLILYDRHLVBEVTSPQAPEGLNRAGKVRPDCMTATTD 68
 Db 3 KTLFDKLWNRHVTYKGEBPQLLIVDHLHTHEVTSQAPEGLNLQRKLRPDLTPATLD 62
 XX
 Qy 69 HNVPTTSRKALKDIAFSIKEYDSRTQCVTLEENVKEFGTVTFLSDERGQVHVGSEQ 128
 Db 63 HNVPTEDIFNIQDLY----ARKQIEALQTNCAEGFTLADNGSDROGLVHMYCPETG 115
 XX
 Qy 129 FTLPGTTVVGCGDSHTSTHGAGFALAFGIGTSEVEHVLATOCLLIKRSKNMRIQVDGELAP 188
 Db 116 LTQPGKIVVCGDSHTATHGAGIAFGIGTSEVEHVFATQTLWQTKPNLIDINGLPT 175
 XX
 Qy 189 GVSXKDVLHLAIGIIGTAGGGAVIPEGSVTIRLSMEARNSICMNSIEGGARAGMVAPD 248
 Db 176 GVVARDILHLIKTYGVDFGTYGALLEFTGETIKNLSDGMTRICNMMAIEGAKYGIQD 235
 XX
 Qy 249 EITFEYLKGRLDAPKIDSPPEWHTKATQWKNLQSDPEGAKYDIDFIDARDIVTLLTGTP 308
 Db 236 DITFEVKGRAFDNF----AKSVDKWRELYSDDDAIFDRYIELDVSTLEPQVITGTPN 290
 XX
 Qy 309 EDVVPITGTVVDPDPETATEAKKADGRMRMLQYNGLKAGTGPMDIPDVDKVFIGCTNSRIED 368
 Db 292 EMGVFSSKAFP----EIKDMNMYERAYEVMGLKPGQTAEQIELGYVFIGSCTNARLSD 344
 XX
 Qy 369 LRAAAAVVKGRKKAPVNVKSAWNVPGSLVKTOAEEGLDKTPEEAPEGEWREPGCSMCLGM 428
 Db 345 LEEARAVVGKVKNNR-ALVPPSRQVNAAESIGLDKIFIEAFWREPGCSMCLGM 403
 PA (INSP) INST PASTEUR.

Db 404 NPDQVPGVHCASTSNRNFGRQGKQARTHLVSPAMAAAINGHIDIRKV 455
 RESULT 13
 AAR54216 standard; protein; 460 AA.
 XX
 AAR54216;
 ID 09-NOV-1994 (first entry)
 XX
 DE L.lactis branched amino acid synthesis leuC gene product.
 XX
 KW branched amino acid; ilv operon; leucine; isoleucine; valine;
 KW biosynthesis; alpha-acetolactate synthase; diacetyl; food flavouring;
 KW attenuation; anti-terminator; Lactococcus.
 XX
 OS Lactococcus lactis (subsp. lactis).
 XX
 FH Location/Qualifiers
 FT Misc-difference 436 /note= "Val residue corresponds to CTG codon"
 XX
 PN FR2696190-A.
 XX
 PD 01-APR-1994.
 XX
 PF 25-SEP-1992; 92FR-0011470.
 XX
 PR 25-SEP-1992; 92FR-0011470.
 XX
 PA (INRG) INRA INST NAT RECH AGRONOMIQUE.
 PA (AGR-) AGRIC & FOOD RES COUNCIL.
 XX
 PI Ehrlich S, Godon J, Renault P;
 XX
 DR WPI; 1994-128287/16.
 DR N-PSDB; AAQ64211.
 XX
 PT DNA coding for alpha-aceto:lactate synthase - for enhancing
 PT di:acetyl prodn. in microorganisms, esp. for mfr. of dairy prods.
 XX
 PS Disclosure; Fig 2; 45pp; French.
 XX
 CC The genes involved in the pathway for synthesis of branched amino
 acids in L.lactis subsp. lactis are organised in two units
 CC containing the leu (including leuC) and ilv genes, respectively.
 CC Both units are necessary for the synthesis of leucine but only the
 CC second unit is required for synthesis of ile and val. The ilvB
 CC and ilvN genes and the subunits of alpha-acetolactate synthase
 CC that they code for are claimed.
 XX
 SQ Sequence 460 AA;

Query Match 28.1%; Score 1138.5; DB 15; Length 460;
 Best Local Similarity 50.4%; Pred. No. 1.7e-92; Gaps 6;
 Matches 240; Conservative 61; Mismatches 154; Indels 21; Gaps 6;

OY 9 OTYLDPKVLOQAHVDEKDGTVLIVIDRHLHEVTSPOAFEGURNAGRKVRPDTLTD 68
 OY 4 KTFDKLWDQHVTAGNEBGPOLYIDHLVHEVTSPOFOGLREAGRVRKDLTYGLD 63
 Db 6 9 HNPTTSRALKDIAKTFEDDSRTQCVTLEENVKEFQVTVFGLSDKXKQHIVWIGEQ 128
 Db 64 HNVPQTQNFNIQDLI-----SKKQIDTFKVNKEFVPAEDPHGKQGIVHWAEEG 116
 OY 129 FFLPGTVTVCQGSHTSTRGAGFALAFGGTSEVEHVLATOCQKRSNMRQVDGELAP 188
 Db 117 RTQPGKIVLVCQGDSHTATNGAGFALAFGGTSEVEHVLATOCQKRSNMRQVDGELAP 176
 OY 189 GYSSKDQVHLAIGGIGTGGTGAIVERICGSVIRSLMSARMSCNMSIEGGRAGAMVAPD 248
 Db 177 GYISKDFILALIKEYGVDAVGVIAVEYSSGDAISDLSMERMICNSIEFGAKIGLMPD 236

Db 249 EITFEVILKGRPLAKYDSDPENHKATQYKQULQSDQAKYDIDVFDADKIVPULTWGTSP 308
 QY |::|:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:|||:
 Db 237 EKTYDVVKGRHAPK---NFEAVSKWKEVLSDAQYDKILSLDVSQIKPVMWTGTPN 292
 QY 309 EDVVPITGV-VFDPETFATEAKKADGRMQLQYMGKAGTPEMDIPUDKVIFGSCNSRIE 367
 XX
 QY 293 -----GMGLFGEKEPEINNDUNYERAOYMDIKPGQFASDILGYIFGSCNARLG 345
 Db 368 DLRAAAAVVKGKRNKANVKSAMWVIGSLVQVTAEREGLKIFERAGFEREAGSMCLG 427
 QY 346 DLEEAQKIGDQHRTAIGL-TGIVVPPSRPVKAALAQGLDKIFKRAFENREPGSACLG 404
 Db 428 MNPDILAPQERCASSTSNRNFGRQGAGGRHLMSPMAAAGIVKLADYKL-TD 482
 QY 405 MNPDQIPEYVHCASTSNRNFGRQGHNARTHVCSPAMAAAIAAGKFVDFVRLVTD 460

RESULT 14
 ABB5452
 ID ABB5452 standard; Protein; 460 AA.
 XX
 AC ABB54552;
 XX
 PN FR2807446-A1.
 XX
 PD 16-MAY-2002 (first entry)
 XX
 DE Lactococcus lactis protein leuC.
 XX
 KW Biosynthesis; biodegradation; lactic bacterium; yogurt; cheese.
 XX
 OS Lactococcus lactis IL1403.
 XX
 PA FR2807446-A1.
 XX
 PD 12-OCT-2001.
 XX
 PF 11-APR-2000; 2000FR-0004630.
 XX
 PR 11-APR-2000; 2000FR-0004630.
 XX
 PA (INRG) INRA INST NAT RECH AGRONOMIQUE.
 XX
 PI Bolotine A, Sorokine A, Renault P, Ehrlich SD;
 XX
 DR WPI; 2002-043418/06.
 XX
 PT New nucleotide sequence useful in the identification or Lactococcus
 PT lactis and related species -
 XX
 PS Claim 6; SEQ ID No 1254; 2504pp; French.
 XX
 CC The present invention is related to a Lactococcus lactis nucleotide
 CC sequence (A8949051) and related proteins (ABB33300-ABB55621). The
 CC nucleic acid sequence is useful in the detection and/or amplification of
 CC nucleic acid sequence, particularly to identify Lactococcus lactis or
 CC nucleic acid sequence, the proteins of the invention are useful for the
 CC biosynthesis or biodegradation of a composition of interest. The
 CC invention helps research in lactic bacteria, particularly useful in the
 CC production of yogurt and cheese.
 Note: The sequence data for this patent is based on equivalent patent
 CC WO00177334 (published 18-Oct-2001) which is available in electronic
 CC format directly from WIPO at ftp.wipo.int/pub/published_pct_sequences.
 XX
 SQ Sequence 460 AA;

Query Match 27.9%; Score 1132.5; DB 23; Length 460;
 Best Local Similarity 50.4%; Pred. No. 5.8e-92; Gaps 6;
 Matches 240; Conservative 59; Mismatches 156; Indels 21; Gaps 6;

QY 9 QTYLDPKVLOQAHVDEKDGTVLIVIDRHLHEVTSPOAFEGURNAGRKVRPDTLTD 68
 Db 4 KTFDKLWDQHVTAGNEBGPOLYIDHLVHEVTSPOFOGLREAGRVRKDLTYGLD 63

PT	useful in vaccines and for treatment of bacterial infections of e.g.
PT	respiratory tract and central nervous system
XX	Claim 11: Page 348-349; 390pp; English.
XX	This sequence represents a <i>Staphylococcus aureus</i> protein, that based on homology with a <i>Lactococcus lactis</i> subsp <i>lactis</i> (<i>Streptococcus lactis</i>) protein, is a 3-isopropylmalate dehydratase (Bc 4.2.1.33) (isopropylmalate isomerase) (Alpha-Ipm isomerase) (Ipm1), and is encoded by a DNA sequence of the invention.
CC	The DNA sequences were isolated from <i>Staphylococcus aureus</i> WCHU29 (NCMB 40771). Host cells containing the DNA sequences are used to produce polypeptides or fragments. The proteins are used in the treatment of disease, for inducing an immune response by administering them, to produce antibody and/or T-cell immune response. Antagonists of the proteins are used for the inhibition of bacterial polypeptides. Conditions which may be treated include bacterial infections, especially respiratory, cardiac, gastrointestinal, central nervous, eye, kidney, urinary tract, skin, bones and joints. The proteins can also be used to identify antimicrobial compounds which are broad spectrum antibiotics, especially useful in the treatment of <i>H. pylori</i> infection.
XX	Sequence 264 AA:
	Query Match 18.5%; Score 749; DB 19; Length 264;
	Best Local Similarity 53.8%; P-req. No. 3.9e-58;
	Matches 147; Conservative 39; Mismatches 75; Indels 12; Gaps 3
Qy	15 VLOAHVVDKLDGTIVLLYIDRHLVHEVTSPOAEGLNRNAGRKYRRPDCTLATTDDHNVPRT 74
Db	1 VWRHLVXGXQDGPQLYIDHLHETVSPQAFEGRLIQNKRKURRPDLFATLDHNVPRTI 60
Qy	75 SRKALKDIAFSIKEEDSRTQCVTLEENVKEFGTYVFGLSDKRQGIVHVIGPEQGQFTLPGT 134
Db	61 -----DIFN-IKDEIANKQITLQKNAIDFGVHIFDGMGSDEQCIHVWGPETGLTQPGK 113
Qy	135 TIVCGSDHTSTHGAFQALAFGIGTSEVHVLATOCLITRTRSKNMRQVQGELAPGVSSKD 194
Db	114 TIVCGSDHTSTHGAFQALAFGIGTSEVHVLQTKPKNLKDINGTLPIGVYAXD 173
Qy	195 VVLHAIIGIIGTAGGTCAVIEFCGSVIRSLSMARMSCICMNSIEGGARAGMVAPDDEITFEX 254
Db	174 IILHIIKTVYDFGIGYALBFGETIKNLMMGRMTICNMAEGGAKYGLIQPDDITFEX 233
Qy	255 LKGRLPLAKYDSDPENWKAQYKWNLQSDPGARY 287
Db	234 VKGRLPFDANP-----AKSVDFKWRLEYSDGTRY 261
	RESULT 16
	AAG81974
	ID AAG81974 standard; Protein; 245 AA.
	XX
	AC AAG81974;
	XX
	DT 03-SEP-2001 (First entry)
	XX
	DB S. epidermidis open reading frame protein sequence SEQ ID NO:1042.
	XX
	KW Staphylococcus epidermidis SR1 strain; infection; diagnosis;
	XX
	OS Staphylococcus epidermidis.
	XX
	PN WO200134809-A2.
	XX
	PD 17-MAY-2001.
	XX
	PP 09-NOV-2000; 2000WO-US30782.
	XX
	PR 09-NOV-1999; 99US-0164258.
	PA (GLAXO) GLAXO GROUP LTD.

XX	DN	FR2792651-A1.
PI	XX	
Kimmerly WJ;	XX	
WPI; 2001-31695/33.	PD	27-OCT-2000.
DR	XX	
N-PSDB; AAH52824.	PF	21-APR-1999; 99FR-0005034.
XX	XX	
PT	PR	21-APR-1999; 99FR-0005034.
PT	XX	
useful for vaccinating against infections, e.g. endocarditis -	PA	(CNRS) CNRS CENT NAT RECH SCI (IFRE-) IFREMER INST FR RBCH BXPL MER.
XX	PA	
PS	XX	
Claim 18; Page 303; 218pp; English.	PT	
XX	XX	
XX	PI	Porterie P, Thierry JC, Prieur D, Dietrich J, Lecompte O;
AAH52304 to AAH53970 represent nucleic acids (I) encoding polypeptides (II), given in AAG81454 to AAC83120, from <i>Staphylococcus epidermidis</i> , (I) and (II) can have antibacterial activity and therefore can be used in vaccination. The nucleic acids (I) may be used to produce the S. epidermidis polypeptides (II) via the production of vectors containing them which are used to produce host cells which express the polypeptides. The polypeptides (II) (and/or nucleic acids) may then be used to vaccinate subjects and to raise antibodies against the bacteria. The polypeptides may also be used to assay for other inhibitors of their activity and therefore identify compounds that may be used for the treatment of S. epidermidis infections, e.g. endocarditis. AAH53971 to AAH55090 represent specifically claimed S. epidermidis genomic DNA polynucleotide sequences from the present invention. AAM55091 to AAH55098 represent oligonucleotide sequences and primers which are used in the exemplification of the present invention. N.B. The present invention specifically claims all the polynucleotide sequences given in the sequence listing of the present specification, however the sequence listing only goes up to SEQ ID NO:4454 so even though sequences are given in the disclosure for SEQ ID NO:4465 to 4472, no sequences are present for SEQ ID NO:4455 to 4464.	PI	Querellou J, Weissenbach J, Saurin W, Heilig R;
XX	PS	WPI; 2001-126236/14.
XX	XX	
CC	CC	New nucleotide sequences isolated from Pyrococcus abyssi encode proteins useful in industry -
CC	CC	
CC	PS	Claim 7; Pages 1038-1040; 165pp; French.
CC	XX	
CC	CC	The present invention relates to the genomic sequence of Pyrococcus abyssi (see AAF6431 and AAH41223-7) and P. abyssi proteins. P. abyssi is a hyperthermophilic archaeon, which is isolated from deep-sea hydrothermal vents. The present sequence is one such P. abyssi protein. The proteins of the present invention have various potential industrial uses, since the proteins are stable at very high temperatures, some up to 110 degrees centigrade.
CC	CC	Note: This patent is in the same patent family as WO200065052, which contains additional sequences as shown in AAB99132-AAB99143, AAH75903-AAH75920 and AAG66436.
CC	XX	
XX	XX	
SQ	Sequence	245 AA;
Query Match	17.0%	Score 688.5; DB 22; Length 245;
Best Local Similarity	53.5%	Pred. No. 8.6e-53; Mismatches 68; Indels 13; Gaps 3;
Matches	137;	Conservative 38;
Db	1	MEARMTCIONMAIEAGAKYGLNQPDETTFNWKGRPVATDFS----SMAWKELYSDD 55
QY	225	MEARMTCIONMAIEAGAKYGLNQPDETTFNWKGRPVATDFS----SMAWKELYSDD 55
Db	56	AYFDKVIELDVNLPEOTWTGGINPENGVFSNPP----EIKVANDORAYDYINGLHP 108
QY	285	AYFDKVIELDVNLPEOTWTGGINPENGVFSNPP----EIKVANDORAYDYINGLHP 108
Db	345	GTPMEDIPDVKFIGSCTNSIEDLAAAUVKGKRAAPNTKSAVPGSGLVKTQAEEE 404
QY	345	GTPMEDIPDVKFIGSCTNSIEDLAAAUVKGKRAAPNTKSAVPGSGLVKTQAEEE 404
Db	109	GOKAEDIKLGLYVFLGSCNTNARLSDLIEASHITKGQVHPNI-TAIWPGSRTVKKSAEL 167
QY	405	GOKAEDIKLGLYVFLGSCNTNARLSDLIEASHITKGQVHPNI-TAIWPGSRTVKKSAEL 167
Db	168	GIDKLFKFDAGEWREGCCSMCILGMNPQDQVPGVHCASTSNRNFEGRKGAARTHLYSPAM 227
QY	465	GIDKLFKFDAGEWREGCCSMCILGMNPQDQVPGVHCASTSNRNFEGRKGAARTHLYSPAM 227
Db	228	AAAAAINGKFDIVRKV 243
RESULT 17		
AAH96358		
ID		
AAB96358 standard; Protein; 423 AA.		
XX		
AC		
AAB96358;		
XX		
DT		
29-OCT-2001 (first entry)		
XX		
DE		
Putative 3-isopropylmalate dehydratase/aconitase large subunit #2.		
XX		
KW		
Hyperthermophilic archaeon; hyperthermophilic protein.		
OS		
Pyrococcus abyssi.		
XX		
RESULT 18		
AAG29924		

ID	AAG29924	standard; Protein; 461 AA.	
XX	AC	AAG29924;	99US-0139461.
XX	XX		99US-0139462.
DT	17-OCT-2000	(first entry)	PR 18-JUN-1999;
XX	XX	Arabidopsis thaliana protein fragment	PR 18-JUN-1999;
XX	DE	SEQ ID NO: 35684.	PR 18-JUN-1999;
XX	KW	protein identification; signal transduction pathway; metabolic pathway;	PR 21-JUN-1999;
XX	KW	hybridisation assay; genetic mapping; gene expression control; promoter;	PR 22-JUN-1999;
XX	KW	termination sequence.	PR 23-JUN-1999;
XX	OS	Arabidopsis thaliana.	PR 23-JUN-1999;
XX	PN	EP1033405-A2.	PR 24-JUN-1999;
XX	PD	06-SEP-2000.	PR 28-JUN-1999;
XX	XX		PR 29-JUN-1999;
PF	25-FEB-2000;	2000EP-0301439.	PR 30-JUN-1999;
XX	PR	25-FEB-1999;	PR 01-JUL-1999;
PR	05-MAR-1999;	99US-0121825.	PR 01-JUL-1999;
PR	09-MAR-1999;	99US-0123180.	PR 01-JUL-1999;
PR	09-MAR-1999;	99US-0123548.	PR 06-JUL-1999;
PR	23-MAR-1999;	99US-0125788.	PR 08-JUL-1999;
PR	23-MAR-1999;	99US-0125789.	PR 09-JUL-1999;
PR	29-MAR-1999;	99US-0126624.	PR 09-JUL-1999;
PR	29-MAR-1999;	99US-0126785.	PR 12-JUL-1999;
PR	01-APR-1999;	99US-0127462.	PR 13-JUL-1999;
PR	06-APR-1999;	99US-0128234.	PR 14-JUL-1999;
PR	08-APR-1999;	99US-0128714.	PR 15-JUL-1999;
PR	19-APR-1999;	99US-0129845.	PR 16-JUL-1999;
PR	19-APR-1999;	99US-0130077.	PR 16-JUL-1999;
PR	21-APR-1999;	99US-0130449.	PR 19-JUL-1999;
PR	23-APR-1999;	99US-0130510.	PR 19-JUL-1999;
PR	23-APR-1999;	99US-0130891.	PR 19-JUL-1999;
PR	28-APR-1999;	99US-0131449.	PR 19-JUL-1999;
PR	30-APR-1999;	99US-0132048.	PR 19-JUL-1999;
PR	04-MAY-1999;	99US-0132407.	PR 19-JUL-1999;
PR	04-MAY-1999;	99US-0132484.	PR 20-JUL-1999;
PR	05-MAY-1999;	99US-0132485.	PR 20-JUL-1999;
PR	06-MAY-1999;	99US-0132486.	PR 20-JUL-1999;
PR	06-MAY-1999;	99US-0132487.	PR 21-JUL-1999;
PR	11-MAY-1999;	99US-0132863.	PR 21-JUL-1999;
PR	14-MAY-1999;	99US-0134256.	PR 21-JUL-1999;
PR	14-MAY-1999;	99US-0134218.	PR 22-JUL-1999;
PR	14-MAY-1999;	99US-0134219.	PR 22-JUL-1999;
PR	14-MAY-1999;	99US-0134421.	PR 22-JUL-1999;
PR	14-MAY-1999;	99US-0133370.	PR 23-JUL-1999;
PR	19-MAY-1999;	99US-0134768.	PR 23-JUL-1999;
PR	20-MAY-1999;	99US-0134941.	PR 23-JUL-1999;
PR	21-JUN-1999;	99US-0135124.	PR 24-AUG-1999;
PR	24-MAY-1999;	99US-0135353.	PR 24-AUG-1999;
PR	25-MAY-1999;	99US-0135629.	PR 24-AUG-1999;
PR	07-JUN-1999;	99US-0136021.	PR 03-AUG-1999;
PR	08-JUN-1999;	99US-0136392.	PR 04-AUG-1999;
PR	28-MAY-1999;	99US-0136782.	PR 04-AUG-1999;
PR	01-JUN-1999;	99US-0136783.	PR 05-AUG-1999;
PR	14-JUN-1999;	99US-0137222.	PR 05-AUG-1999;
PR	04-JUN-1999;	99US-0137528.	PR 05-AUG-1999;
PR	16-JUN-1999;	99US-0137502.	PR 06-AUG-1999;
PR	16-JUN-1999;	99US-0137724.	PR 06-AUG-1999;
PR	17-JUN-1999;	99US-0138094.	PR 09-AUG-1999;
PR	18-JUN-1999;	99US-0138540.	PR 09-AUG-1999;
PR	18-JUN-1999;	99US-0138847.	PR 10-AUG-1999;
PR	18-JUN-1999;	99US-0139119.	PR 11-AUG-1999;
PR	18-JUN-1999;	99US-0139452.	PR 12-AUG-1999;
PR	18-JUN-1999;	99US-0139453.	PR 13-AUG-1999;
PR	17-JUN-1999;	99US-0139454.	PR 13-AUG-1999;
PR	18-JUN-1999;	99US-0139455.	PR 16-AUG-1999;
PR	18-JUN-1999;	99US-0139456.	PR 17-AUG-1999;
PR	18-JUN-1999;	99US-0139457.	PR 18-AUG-1999;
PR	18-JUN-1999;	99US-0139458.	PR 20-AUG-1999;
PR	18-JUN-1999;	99US-0139459.	PR 20-AUG-1999;
PR	18-JUN-1999;	99US-0139460.	PR 23-AUG-1999;

PR	23-AUG-1999;	99US-0149930.	Db	183 LKVPPTMRFILDGEMPSYLOAKDILQIGEISVAGATYKIMFEGSTIESLMEERMTL 242
PR	26-AUG-1999;	99US-0150565.	Qy	232 CNMSTEGGARAGRMWAPDETOFEYLKGRPLA---PKYDSPEMKKATQYWKNUQSPEAKYD 288
PR	27-AUG-1999;	99US-0151065.	Db	243 CNMVVYEAEGKNGKGVFPDATTLYVACILSCFLPVT-----SDGNASFV 286
PR	27-AUG-1999;	99US-0151080.		
PR	30-AUG-1999;	99US-0151303.	Qy	289 IDVFDIADKVPLTWGTSEDBVVITGVVPDPETPATEAKKADGRMLQYMGKAGTPM 348
PR	01-SEP-1999;	99US-0151438.	Db	287 ADYRFEDVSKLEPVV---AKBHS-----PDNRALECK----- 316
PR	07-SEP-1999;	99US-0152363.		
PR	10-SEP-1999;	99US-0153070.	Qy	349 EDIPVDFKVFQGSCMNSRIEDLRAAAV--VKGKRKAPNV-----KSAMYVPGS 394
PR	13-SEP-1999;	99US-0153758.		
PR	15-SEP-1999;	99US-0154018.	Db	317 -DVKIDRIVVIGSCIGKTEDFMALAKLFLHAGRAKVKUPTFLVATOKWMDVYALFVPGA 375
PR	16-SEP-1999;	99US-0154039.		
PR	20-SEP-1999;	99US-0154779.	Qy	395 GLVKTQAESEGLDKFEEAGFEEW REAGESMCMLGKMNPDIA---PQERCASTSNENFEG 449
PR	22-SEP-1999;	99US-0155139.	Db	376 G-GKTCAO-----IFEEAGCDTPASPSCGACLGGPADTYARLNEPQV-CVSTTNRNPFG 427
PR	23-SEP-1999;	99US-0155486.		
PR	24-SEP-1999;	99US-0155639.		
PR	28-SEP-1999;	99US-0156458.		
PR	04-OCT-1999;	99US-0157117.	Qy	450 RQG-AGGRPHLMSPMAAAGIVGKLADRVK 479
PR	05-OCT-1999;	99US-0157753.	Db	428 RMGKKEGQTYLASPYTAASALTGRVADPRE 458
PR	06-OCT-1999;	99US-0158865.		
PR	07-OCT-1999;	99US-0158929.		
PR	08-OCT-1999;	99US-0158932.		
PR	12-OCT-1999;	99US-0158969.		
PR	13-OCT-1999;	99US-0159293.	AAAG0226	ID AAG40226 standard; Protein; 469 AA.
PR	13-OCT-1999;	99US-0159294.	XX	
PR	13-OCT-1999;	99US-0159295.	AC	
PR	14-OCT-1999;	99US-0159329.	XX	
PR	14-OCT-1999;	99US-0159330.	DT	
PR	14-OCT-1999;	99US-0159331.	XX	
PR	14-OCT-1999;	99US-0159537.	DE	
PR	14-OCT-1999;	99US-0159638.	XX	
PR	18-15-OCT-1999;	99US-015984.	KW	
PR	21-OCT-1999;	99US-0160741.	KW	
PR	21-OCT-1999;	99US-0160767.	KW	
PR	21-OCT-1999;	99US-0160768.	OS	
PR	21-OCT-1999;	99US-0160770.	XX	
PR	21-OCT-1999;	99US-0160814.	XX	
PR	21-OCT-1999;	99US-0160815.	PN	
PR	22-OCT-1999;	99US-0160980.	XX	
PR	22-OCT-1999;	99US-0160981.	PD	
PR	22-OCT-1999;	99US-0160989.	XX	
PR	25-OCT-1999;	99US-0161404.	PP	
PR	25-OCT-1999;	99US-0161405.	XX	
PR	25-OCT-1999;	99US-0161406.	PR	
PR	26-OCT-1999;	99US-0161359.	PR	
PR	26-OCT-1999;	99US-0161360.	PR	
PR	26-OCT-1999;	99US-0161361.	PR	
PR	28-OCT-1999;	99US-0161920.	PR	
PR	28-OCT-1999;	99US-0161992.	PR	
PR	28-OCT-1999;	99US-0161993.	PR	
PR	29-OCT-1999;	99US-0162142.	PR	

Query Match 13 8%; Score 558.5; DB 21; Length 461;
 Best Local Similarity 32.1%; Pred. No. 9.4e-41; DB 21;
 Matches 164; Conservative 73; Mismatches 175; Indels 99; Gaps 22;

Qy	3 GAASPTPQTYDVKVQAHVDEKL--DGTVLVLVDRHLYHEVTSQAFEGU--RNAGRKV 57	
Db	13 GSVKIGMNTMEKIL-ARASPSLWVPGDNIWNVNVDVLMTDVGPGAF-GIFKRERGEKA 70	
Qy	58 R--RPDCIATTDHNVPTSRKALKDIASPIKEDSRTQCVTLEENKEF---GVYFG 111	
Db	71 KWDPEKEVIVPDHYIFTADKRAMRNV----DIMREHC--REGNIKPYDITDGNFK 122	
Qy	112 LSDKRQGTIVHIGPEQGFTLPGTVVCGIHSHTGAFGALAFGIGTSEVERVHATQCLL 171	
Db	123 ANPDYKGVCHVALLAQEGHCRGPGEVLTGTSHTCTAGAFQOFATGIGNTAGFVLTGKIL 182	
Qy	172 TKEKSKNMRJLQVQDGLAPGSSKDVTLHAJIGIIGRAGTGTAVIECGSVRSLMEARMSI 231	

PR	19-MAY-1999;	99US-0134941.	99US-0145951.
PR	20-MAY-1999;	99US-0125124.	99US-0146386.
PR	21-MAY-1999;	99US-0135153.	99US-0146388.
PR	24-MAY-1999;	99US-0135629.	99US-0146389.
PR	25-MAY-1999;	99US-0136021.	99US-0147038.
PR	27-MAY-1999;	99US-0136192.	99US-0147204.
PR	28-MAY-1999;	99US-0136782.	99US-0147302.
PR	01-JUN-1999;	99US-0137224.	99US-0147192.
PR	03-JUN-1999;	99US-0137518.	99US-0147260.
PR	04-JUN-1999;	99US-0137502.	99US-0147203.
PR	07-JUN-1999;	99US-0137724.	99US-0147303.
PR	08-JUN-1999;	99US-0138044.	99US-0147416.
PR	10-JUN-1999;	99US-0138540.	99US-0147493.
PR	14-JUN-1999;	99US-0138847.	99US-0148319.
PR	16-JUN-1999;	99US-0139422.	99US-0148341.
PR	16-JUN-1999;	99US-0139433.	99US-0148565.
PR	17-JUN-1999;	99US-0139422.	99US-0148684.
PR	18-JUN-1999;	99US-0139454.	99US-0149368.
PR	18-JUN-1999;	99US-0139455.	99US-0149175.
PR	18-JUN-1999;	99US-0139459.	99US-0149426.
PR	18-JUN-1999;	99US-0139457.	99US-0149722.
PR	18-JUN-1999;	99US-0139458.	99US-0149723.
PR	18-JUN-1999;	99US-0139450.	99US-0149929.
PR	18-JUN-1999;	99US-0139452.	99US-0149902.
PR	18-JUN-1999;	99US-0139460.	99US-0149930.
PR	18-JUN-1999;	99US-0139461.	99US-0150566.
PR	18-JUN-1999;	99US-0139462.	99US-0150884.
PR	18-JUN-1999;	99US-0139463.	99US-0151065.
PR	24-JUN-1999;	99US-0139750.	99US-0151066.
PR	28-JUN-1999;	99US-0139762.	99US-0151080.
PR	21-JUN-1999;	99US-0139817.	99US-0151303.
PR	22-JUN-1999;	99US-0139899.	99US-0151438.
PR	23-JUN-1999;	99US-0140353.	99US-0151930.
PR	24-JUN-1999;	99US-0140354.	99US-0152363.
PR	02-JUL-1999;	99US-0140695.	99US-0152753.
PR	06-JUL-1999;	99US-0140823.	99US-0153070.
PR	08-JUL-1999;	99US-0140991.	99US-0153758.
PR	30-JUN-1999;	99US-0141287.	99US-0154018.
PR	01-JUL-1999;	99US-0141842.	99US-0154939.
PR	01-JUL-1999;	99US-014154.	99US-0154779.
PR	02-JUL-1999;	99US-0142055.	99US-0155139.
PR	06-JUL-1999;	99US-0142390.	99US-0155486.
PR	08-JUL-1999;	99US-0142003.	99US-0155659.
PR	09-JUL-1999;	99US-0142920.	99US-0156558.
PR	12-JUL-1999;	99US-0142977.	99US-0156916.
PR	13-JUL-1999;	99US-0143542.	99US-0157117.
PR	14-JUL-1999;	99US-0143624.	99US-0157753.
PR	15-JUL-1999;	99US-0144005.	99US-0157865.
PR	16-JUL-1999;	99US-0144085.	99US-0158029.
PR	19-JUL-1999;	99US-0144334.	99US-0158232.
PR	16-JUL-1999;	99US-0144086.	99US-0158339.
PR	19-JUL-1999;	99US-0144325.	99US-0159311.
PR	19-JUL-1999;	99US-0144331.	99US-0159233.
PR	19-JUL-1999;	99US-0144332.	99US-0159234.
PR	19-JUL-1999;	99US-0144333.	99US-0159235.
PR	19-JUL-1999;	99US-0144334.	99US-0159236.
PR	21-JUL-1999;	99US-0144814.	99US-0160741.
PR	21-JUL-1999;	99US-014486.	99US-0160980.
PR	21-JUL-1999;	99US-0144335.	99US-0160981.
PR	22-JUL-1999;	99US-0145085.	99US-0160989.
PR	22-JUL-1999;	99US-0144632.	99US-0160770.
PR	22-JUL-1999;	99US-0144587.	99US-0160814.
PR	22-JUL-1999;	99US-0145089.	99US-0160815.
PR	23-JUL-1999;	99US-0145192.	99US-0160980.
PR	23-JUL-1999;	99US-0145145.	99US-0160981.
PR	23-JUL-1999;	99US-0145218.	99US-0160989.
PR	23-JUL-1999;	99US-014524.	99US-0161404.
PR	26-JUL-1999;	99US-0145276.	99US-0161405.
PR	27-JUL-1999;	99US-014513.	99US-0161406.
PR	27-JUL-1999;	99US-014518.	99US-0161359.
PR	27-JUL-1999;	99US-014519.	99US-0161359.

ABB9224 standard; Protein; 509 AA.
 XX
 AC
 XX
 DT 31-MAY-2002 (first entry)
 DE Herbicidally active polypeptide SEQ ID NO 2135.
 XX
 KW Herbicidal; plant; agriculture; herbicide.
 XX
 OS *Arabidopsis thaliana*.
 XX
 PN WO200210210-A2.
 XX
 PD 07-FEB-2002.
 XX
 PR 28-AUG-2001; 2001WO-EP09892.
 XX
 PA (FARB) BAYER AG.
 XX
 PI Tietjen K, Weidler M;
 XX
 DR WPI; 2002-269010/31.
 XX
 PT Identifying plant target proteins for herbicidally active compounds, comprising aligning and comparing nucleic acid or amino acid sequences from plant organisms -
 PT comprising aligning and comparing nucleic acid or amino acid sequences from non-plant organisms -
 PT aligning and comparing nucleic acid or amino acid sequences from non-plant organisms using suitable search parameters, where plant sequences having an E-value greater by a factor of 3 than the E-value of most similar non-plant sequences are selected. The polypeptides or nucleic acids encoding the are useful for identifying modulators. The identified modulators are useful as herbicides.
 CC
 CC (ABB90790-ABB4016) for herbicidally active compounds, comprising aligning and comparing nucleic acid or amino acid sequences from plant organisms using suitable search parameters, where plant sequences having an E-value greater by a factor of 3 than the E-value of most similar non-plant sequences are selected. The polypeptides or nucleic acids encoding the are useful for identifying modulators. The identified modulators are useful as herbicides.
 CC
 SQ Sequence 509 AA;
 Query Match 13 8%; Score 558 5; DB 23; Length 509;
 Best Local Similarity 32.1%; Pred. No. 1.1e-40;
 Matches 164; Conservative 73; Mismatches 175; Indels 99; Gaps 0;
 QY 3 GAESTPQTQLYDKVLOAHVVDKLU--DGTVLLYIDRHLVHEVTPSQAEGL--RNAGRKV 57
 DB 61 GSVKKGMTMPKEILU-ARASEEKSLLVPGDNIUWVNDLWLMHDVCGPGAF-GIFKREFGBKA 118
 QY 58 R--RDRCTLQTDTRHNPTRSKAKDIAASPIKEDSRTOCUTLBNENKF--GVVTFG 111
 DB 119 KVWDPKEKIVVLPDHVIFTADKRKRNKV----DIMREK- REQNIVKFYDITDGNFK 1700
 QY 112 LSDRKQGIVHVGIGBQGFPLPGTIVWCGSHTSPHGFARLARGIGCSEVERVLTQCLL 171
 DB 171 ANPDYKGVCHVALAQEGHRRPGEVLLGTDHTCTAGAFQPATGIGNTDAFGVLTGKIL 2300
 QY 172 TKRSKMRQVGDGELAPGVSSEKDVVLHAIGIITAGGQAVIEFCGSVIRSLSMEARNSTI 2311
 DB 231 LKVPPIMRFLDGENPSVQIQLDILQIIGEISYAGATVKTMEBSGTTIESLSMEERNIL 2900
 QY 232 CNMSTEGGAGAAGMVADEDTPEYKGRPA--PKYDSPEWKATQYWNLQSDPGAKYD 2888
 DB 291 CNMVVEAGKNGKVGIPDATTLYVACIUSCFLVY----- SDGNASFV 3349
 QY 289 IDVFDIADKIVPTLWGTSPEDWVPIGVVPPDPFATEAKKADGRMRMLQYMGULKAGTM 3488

PR	PR	03-JUN-1999	99US-0137528.
PR	PR	04-JUN-1999	99US-0137502.
PR	PR	07-JUN-1999	99US-013774.
PR	PR	08-JUN-1999	99US-0130094.
PR	PR	10-JUN-1999	99US-0135540.
PR	PR	10-JUN-1999	99US-0138847.
PR	PR	14-JUN-1999	99US-0139119.
PR	PR	16-JUN-1999	99US-0139452.
PR	PR	16-JUN-1999	99US-0139153.
PR	PR	17-JUN-1999	99US-0139492.
PR	PR	18-JUN-1999	99US-0139454.
PR	PR	18-JUN-1999	99US-0139455.
PR	PR	18-JUN-1999	99US-0139456.
PR	PR	18-JUN-1999	99US-0139457.
PR	PR	18-JUN-1999	99US-0139458.
PR	PR	18-JUN-1999	99US-0139459.
PR	PR	18-JUN-1999	99US-0139460.
PR	PR	18-JUN-1999	99US-0139461.
PR	PR	18-JUN-1999	99US-0139462.
PR	PR	18-JUN-1999	99US-0139463.
PR	PR	22-JUN-1999	99US-0139467.
PR	PR	23-JUN-1999	99US-0140354.
PR	PR	24-JUN-1999	99US-0140695.
PR	PR	28-JUN-1999	99US-0140823.
PR	PR	29-JUN-1999	99US-0140991.
PR	PR	30-JUN-1999	99US-0141287.
PR	PR	01-JUL-1999	99US-0141842.
PR	PR	01-JUL-1999	99US-0142154.
PR	PR	02-JUL-1999	99US-0142455.
PR	PR	06-JUL-1999	99US-0142390.
PR	PR	08-JUL-1999	99US-0142803.
PR	PR	09-JUL-1999	99US-0142920.
PR	PR	12-JUL-1999	99US-0142977.
PR	PR	13-JUL-1999	99US-0143542.
PR	PR	14-JUL-1999	99US-0143624.
PR	PR	15-JUL-1999	99US-0144005.
PR	PR	16-JUL-1999	99US-0144085.
PR	PR	16-JUL-1999	99US-0144086.
PR	PR	19-JUL-1999	99US-0144325.
PR	PR	19-JUL-1999	99US-0144331.
PR	PR	19-JUL-1999	99US-0144332.
PR	PR	20-JUL-1999	99US-0144333.
PR	PR	20-JUL-1999	99US-0144884.
PR	PR	21-JUL-1999	99US-0144814.
PR	PR	21-JUL-1999	99US-0145086.
PR	PR	21-JUL-1999	99US-0145145.
PR	PR	22-JUL-1999	99US-0145088.
PR	PR	22-JUL-1999	99US-0145352.
PR	PR	22-JUL-1999	99US-0145087.
PR	PR	22-JUL-1999	99US-0145276.
PR	PR	27-JUL-1999	99US-0145913.
PR	PR	27-JUL-1999	99US-0145918.
PR	PR	27-JUL-1999	99US-0145919.
PR	PR	28-JUL-1999	99US-0145151.
PR	PR	23-JUL-1999	99US-015224.
PR	PR	26-JUL-1999	99US-0145386.
PR	PR	27-JUL-1999	99US-0145388.
PR	PR	02-AUG-1999	99US-0146389.
PR	PR	03-AUG-1999	99US-0141038.
PR	PR	04-AUG-1999	99US-0141204.
PR	PR	05-AUG-1999	99US-0147302.

Query	Match
05-AUG-1999;	
06-AUG-1999;	
07-AUG-1999;	
08-AUG-1999;	
09-AUG-1999;	
10-AUG-1999;	
11-AUG-1999;	
12-AUG-1999;	
13-AUG-1999;	
14-AUG-1999;	
15-AUG-1999;	
16-AUG-1999;	
17-AUG-1999;	
18-AUG-1999;	
20-AUG-1999;	
21-AUG-1999;	
23-AUG-1999;	
25-AUG-1999;	
26-AUG-1999;	
27-AUG-1999;	
27-AUG-1999;	
27-AUG-1999;	
30-AUG-1999;	
31-AUG-1999;	
01-SEP-1999;	
07-SEP-1999;	
10-SEP-1999;	
13-SEP-1999;	
15-SEP-1999;	
16-SEP-1999;	
20-SEP-1999;	
22-SEP-1999;	
23-SEP-1999;	
24-SEP-1999;	
28-SEP-1999;	
29-SEP-1999;	
04-OCT-1999;	
05-OCT-1999;	
06-OCT-1999;	
07-OCT-1999;	
08-OCT-1999;	
12-OCT-1999;	
13-OCT-1999;	
13-OCT-1999;	
13-OCT-1999;	
14-OCT-1999;	
18-OCT-1999;	
21-OCT-1999;	
21-OCT-1999;	
22-OCT-1999;	
22-OCT-1999;	
25-OCT-1999;	
25-OCT-1999;	
25-OCT-1999;	
26-OCT-1999;	
26-OCT-1999;	
26-OCT-1999;	
28-OCT-1999;	
28-OCT-1999;	
28-OCT-1999;	
29-OCT-1999;	

990US-0147260-
990US-0147303-
990US-0147416-
990US-0147935-
990US-0148171-
990US-0148319-
990US-0148341-
990US-0148565-
990US-0148684-
990US-0149368-
990US-0149475-
990US-0149426-
990US-0149722-
990US-0149733-
990US-0149929-
990US-0149902-
990US-0149930-
990US-0150566-
990US-0150884-
990US-0151065-
990US-0151106-
990US-0151080-
990US-0151303-
990US-0114438-
990US-0151930-
990US-0152363-
990US-0153070-
990US-0153758-
990US-0154018-
990US-0154039-
990US-0154779-
990US-0155159-
990US-0155486-
990US-0155659-
990US-0156458-
990US-0156596-
990US-0157117-
990US-0157753-
990US-0157865-
990US-0158029-
990US-0158232-
990US-0158369-
990US-0159293-
990US-0159494-
990US-0159295-
990US-0159296-
990US-0159329-
990US-0159330-
990US-0159331-
990US-0159637-
990US-0159638-
990US-0159584-
990US-0160741-
990US-0160767-
990US-0160768-
990US-0160770-
990US-0160814-
990US-0161406-
990US-0161408-
990US-0161359-
990US-0161360-
990US-0161361-
990US-0161920-
990US-0161992-
990US-0162142-
13.8% /

Query Match 13.8%; Score 558.5; DB 21; Length 517;

Best Local Similarity 31.6%: Pred. No. 1. 1e-40;		Matches 164; Conservative 72; Mismatches 176; Indels 107; Gaps 22;	PR 21-APR-1999; 99US-0130419.
QY 3	GAESTPOTLYDKVTLQAHVVDKEKU--DGTVLILYIDRHILHEVTSPOAPEGI--RNAGRKV 57		PR 23-APR-1999; 99US-0130510.
PR 61	GSKVKGTMTEKIL-ARASEKSLVVPQDNIWNVDVLMTHDCGGPAF-GIFKREGEKA 118		PR 23-APR-1999; 99US-0130891.
QY 58	R--RPDCLATPDHNVPTSRKALKOIASFIKEDDSRTQCVLEENKEF---GTVYFG 111		PR 28-APR-1999; 99US-0131459.
PR 119	KWMDPEKTIKVIWIPDHYIFTADKRANRV----DIMREHC--REQNQKYDITDGNFK 170		PR 30-APR-1999; 99US-0132407.
QY 112	LSDKROGIVHVGPEOQFTLPGTVVGGDSHTHGFAGLAFFGIGTSEVEHVLATQCLL 171		PR 04-MAY-1999; 99US-0132484.
PR 171	ANPDYKGVCHVALAQBGHCRBGEVLUCLGTDHTAGFQATGIFTAGVFLGTGKIL 230		PR 05-MAY-1999; 99US-0132485.
QY 172	TRRSKNNRIQVDGELAPGVSSKDVVLHAIGITGAGTGAIVTEFCSSVIRSLSMEARNSI 231		PR 06-MAY-1999; 99US-0132487.
PR 231	LKVUPPTMVFILDGEMPSYLIQAKDLILQLOIIGEVAGVYKTMFSGTIESSMERMTL 290		PR 07-MAY-1999; 99US-0132863.
QY 232	CNMSIISGGARAGMVADEITFEYLK----GRPLAKYDSBEMHKATQYWMNLQ 280		PR 11-MAY-1999; 99US-0134256.
PR 291	CNNVVEAGKGKONGVIPPDATTINYVEACTLSCFLNRTSVFPEPVY----- 334		PR 14-MAY-1999; 99US-0134218.
QY 281	SDPGAKYDDIDVFAKDVIVPTLWGTSPEDVVPITGVWDPPTFATEAKKADGRRLQIYM 340		PR 14-MAY-1999; 99US-0134219.
PR 335	SDGNASPAFVADTRFDVSKPEVY---AKPHS-----PDNALARCK----- 372		PR 14-MAY-1999; 99US-0134219.
QY 341	GLKAGTPMEDIPDVKVFITGSCTNRSRIDLRAAAAV--VKGRK-KAPNW-----K 386		PR 14-MAY-1999; 99US-0134370.
PR 373	-----DKIDRVIGLGSCTQGKTBDFMAAKLFLHAGRKVNVFPLVPAQTKQVMMDV 423		PR 18-MAY-1999; 99US-0134768.
QY 387	SAMWVPGSGLVLUKQQAEEBGLDKIFEEAGFEEW-REAGCSMCLGMNPDLIA---POERCAS 441		PR 19-MAY-1999; 99US-0135491.
PR 424	YALPVPGG-G-KHICAO-----IFEEAGCDTPASPSCGACUGGPADTYARLINEPQV-CVS 475		PR 20-MAY-1999; 99US-0135533.
QY 442	TSNRNFCCRQG AGGRITHLMSYUMAAAGIVGKLAQFR 479		PR 21-MAY-1999; 99US-0135533.
PR 476	TINRNFPGRMGHKEGQYLASPYTAASSALTGRVADPFR 514		PR 24-MAY-1999; 99US-0135629.
RESULT 23			PR 23-MAY-1999; 99US-0136021.
PR ARG2925			PR 27-MAY-1999; 99US-0136392.
PR ID AAG29925	standard; Protein: 443 AA.		PR 28-MAY-1999; 99US-0136782.
PR AC XX			PR 01-JUN-1999; 99US-0137222.
PR XX	AAG29925;		PR 03-JUN-1999; 99US-0137528.
DT 17-OCT-2000	(first entry)		PR 04-JUN-1999; 99US-0137502.
XX			PR 07-JUN-1999; 99US-0137724.
DE	Arabidopsis thaliana protein fragment SEQ ID NO: 31685.		PR 08-JUN-1999; 99US-0138094.
XX	Protein identification; signal transduction pathway; metabolic pathway; hybridisation assay; genetic mapping; gene expression control; promoter; termination sequence.		PR 10-JUN-1999; 99US-0138540.
XX	Arabidopsis thaliana		PR 10-JUN-1999; 99US-0138847.
OS	Arabidopsis thaliana.		PR 14-JUN-1999; 99US-0139119.
XX			PR 16-JUN-1999; 99US-0139452.
XX			PR 16-JUN-1999; 99US-0139453.
XX			PR 17-JUN-1999; 99US-0139492.
XX			PR 18-JUN-1999; 99US-0139454.
XX			PR 18-JUN-1999; 99US-0139455.
XX			PR 18-JUN-1999; 99US-0139457.
XX			PR 18-JUN-1999; 99US-0139458.
XX			PR 18-JUN-1999; 99US-0139459.
XX			PR 18-JUN-1999; 99US-0139460.
XX			PR 18-JUN-1999; 99US-0139461.
XX			PR 18-JUN-1999; 99US-0139462.
XX			PR 18-JUN-1999; 99US-0139463.
XX			PR 18-JUN-1999; 99US-0139750.
XX			PR 18-JUN-1999; 99US-0139763.
XX			PR 21-JUN-1999; 99US-0139817.
XX			PR 22-JUN-1999; 99US-0139899.
XX			PR 23-JUN-1999; 99US-0140353.
XX			PR 24-JUN-1999; 99US-0140354.
XX			PR 28-JUN-1999; 99US-0140695.
XX			PR 29-JUN-1999; 99US-0140823.
XX			PR 30-JUN-1999; 99US-0140991.
XX			PR 01-JUL-1999; 99US-0141287.
XX			PR 01-JUL-1999; 99US-0141842.
XX			PR 01-JUL-1999; 99US-0142154.
XX			PR 02-JUL-1999; 99US-0142055.
XX			PR 06-JUL-1999; 99US-0142390.
XX			PR 08-JUL-1999; 99US-0142803.
XX			PR 09-JUL-1999; 99US-0142977.
XX			PR 12-JUL-1999; 99US-0143542.
XX			PR 13-JUL-1999; 99US-0143542.
XX			PR 14-JUL-1999; 99US-0143624.
XX			PR 02-JUL-1999; 99US-0144005.
XX			PR 16-JUL-1999; 99US-0144085.
XX			PR 16-JUL-1999; 99US-0144086.
XX			PR 19-JUL-1999; 99US-0144325.
XX			PR 19-JUL-1999; 99US-0144331.
XX			PR 19-JUL-1999; 99US-0144333.
XX			PR 19-JUL-1999; 99US-0144334.
XX			PR 19-JUL-1999; 99US-0144335.

Arabidopsis thaliana Protein fragment SEQ ID NO: 49884.		PR	22-JUN-1999;	99US-0139899
KW	Protein identification; signal transduction pathway; metabolic pathway;	PR	23-JUN-1999;	99US-0140353
KW	hybridisation assay; genetic mapping; gene expression control; promoter;	PR	23-JUN-1999;	99US-0140354
KW	termination sequence.	PR	24-JUN-1999;	99US-0140695
XX		PR	28-JUN-1999;	99US-0140823
OS	Arabidopsis thaliana.	PR	29-JUN-1999;	99US-0140991
XX		PR	30-JUN-1999;	99US-0142803
PN	EP1033405-A2.	PR	01-JUL-1999;	99US-0141842
PN		PR	01-JUL-1999;	99US-0142154
PD	06-SEP-2000.	PR	02-JUL-1999;	99US-0142055
XX		PR	06-JUL-1999;	99US-0142390
PR	25-FEB-2000; 2000EP-0301439.	PR	08-JUL-1999;	99US-0142920
PR	25-FEB-1999;	PR	09-JUL-1999;	99US-0142977
PR	05-MAR-1999;	PR	12-JUL-1999;	99US-0143542
PR	09-MAR-1999;	PR	13-JUL-1999;	99US-0143542
PR	23-MAR-1999;	PR	14-JUL-1999;	99US-0143624
PR	25-MAR-1999;	PR	15-JUL-1999;	99US-0144005
PR	29-MAR-1999;	PR	16-JUL-1999;	99US-0144085
PR	01-APR-1999;	PR	17-JUL-1999;	99US-0144333
PR	06-APR-1999;	PR	18-JUL-1999;	99US-0144334
PR	08-APR-1999;	PR	19-JUL-1999;	99US-0144335
PR	16-APR-1999;	PR	19-JUL-1999;	99US-0144335
PR	19-APR-1999;	PR	19-JUL-1999;	99US-0144325
PR	21-APR-1999;	PR	20-JUL-1999;	99US-0144632
PR	23-APR-1999;	PR	20-JUL-1999;	99US-0144884
PR	28-APR-1999;	PR	21-JUL-1999;	99US-0145182
PR	30-APR-1999;	PR	21-JUL-1999;	99US-0145086
PR	30-APR-1999;	PR	21-JUL-1999;	99US-0145088
PR	04-MAY-1999;	PR	22-JUL-1999;	99US-0145085
PR	05-MAY-1999;	PR	22-JUL-1999;	99US-0145087
PR	06-MAY-1999;	PR	22-JUL-1999;	99US-0145182
PR	07-MAY-1999;	PR	23-JUL-1999;	99US-0145143
PR	11-MAY-1999;	PR	23-JUL-1999;	99US-0145143
PR	14-MAY-1999;	PR	23-JUL-1999;	99US-0145224
PR	14-MAY-1999;	PR	26-JUL-1999;	99US-0145216
PR	14-MAY-1999;	PR	27-JUL-1999;	99US-0145913
PR	14-MAY-1999;	PR	27-JUL-1999;	99US-0145918
PR	19-MAY-1999;	PR	27-JUL-1999;	99US-0145919
PR	20-MAY-1999;	PR	28-JUL-1999;	99US-0145951
PR	21-MAY-1999;	PR	02-AUG-1999;	99US-0146380
PR	24-MAY-1999;	PR	02-AUG-1999;	99US-0146388
PR	25-MAY-1999;	PR	02-AUG-1999;	99US-0146389
PR	27-MAY-1999;	PR	03-AUG-1999;	99US-0147038
PR	28-MAY-1999;	PR	04-AUG-1999;	99US-0147204
PR	01-JUN-1999;	PR	04-AUG-1999;	99US-0147433
PR	03-JUN-1999;	PR	05-AUG-1999;	99US-0147192
PR	04-JUN-1999;	PR	05-AUG-1999;	99US-0147260
PR	07-JUN-1999;	PR	06-AUG-1999;	99US-0147303
PR	08-JUN-1999;	PR	06-AUG-1999;	99US-0147416
PR	10-JUN-1999;	PR	09-AUG-1999;	99US-0147433
PR	10-JUN-1999;	PR	09-AUG-1999;	99US-0147433
PR	16-JUN-1999;	PR	10-AUG-1999;	99US-0148171
PR	16-JUN-1999;	PR	11-AUG-1999;	99US-0148319
PR	18-JUN-1999;	PR	12-AUG-1999;	99US-0149222
PR	18-JUN-1999;	PR	13-AUG-1999;	99US-014565
PR	18-JUN-1999;	PR	13-AUG-1999;	99US-0148634
PR	18-JUN-1999;	PR	16-AUG-1999;	99US-0149902
PR	18-JUN-1999;	PR	17-AUG-1999;	99US-0149168
PR	18-JUN-1999;	PR	18-AUG-1999;	99US-0149466
PR	18-JUN-1999;	PR	18-AUG-1999;	99US-0149466
PR	18-JUN-1999;	PR	19-AUG-1999;	99US-0149466
PR	18-JUN-1999;	PR	20-AUG-1999;	99US-0150856
PR	18-JUN-1999;	PR	20-AUG-1999;	99US-0150856
PR	18-JUN-1999;	PR	27-AUG-1999;	99US-0151065
PR	21-JUN-1999;	PR	27-AUG-1999;	99US-0151065
PR	21-JUN-1999;	PR	27-AUG-1999;	99US-0151080

PR	30-AUG-1999;	99US-0151303.	Qy	288 DIDVFIDAKDIVEPTLWGTSPDVPPETATEAKIADGGERMLQYNGLKAAGTP	347
PR	31-AUG-1999;	99US-0151438.	Db	276 VADYRFVSKLEBVV--AKPHS-----PONRAJARECK-----	306
PR	01-SEP-1999;	99US-0151530.	Qy	248 MEDIPVDKVFIGSCTNSRIEDRAAAV--VKGRK--KAPNV-----KSAMVPG	393
PR	07-SEP-1999;	99US-0152363.	Db	307 -DVKIDRIVYIGSCTGKTEDMWAALFLHAAAGRKVPTFLVATQWMDYALPVPG	364
PR	10-SEP-1999;	99US-0153070.	Qy	394 SGIVKTKQABEEGLDKEFAGQFVW-REAGCSMCLGMNPILA---PQRCFASFSNRNF	448
PR	13-SEP-1999;	99US-0153758.	Db	365 AG-GKTCQ-----IFBEGCDTPASPSCGACLGPPADTYARLINEPQV-CVSTTNRNFP	416
PR	15-SEP-1999;	99US-0154018.	Qy	449 GROG-AGGRTHLMSPVMAAAGIVGKLADRVK	479
PR	16-SEP-1999;	99US-0154433.	Db	417 GRNGHKCQIYLASPYTAASALTGRVADPRE	448
PR	20-SEP-1999;	99US-0154719.			
PR	22-SEP-1999;	99US-0155139.			
PR	23-SEP-1999;	99US-0155486.			
PR	24-SEP-1999;	99US-0155659.			
PR	28-SEP-1999;	99US-0156438.			
PR	29-SEP-1999;	99US-0156516.			
PR	04-OCT-1999;	99US-0157117.			
PR	05-OCT-1999;	99US-0157753.			
PR	06-OCT-1999;	99US-0157835.			
PR	07-OCT-1999;	99US-0158039.			
PR	08-OCT-1999;	99US-0158212.			
PR	12-OCT-1999;	99US-0158399.			
PR	13-OCT-1999;	99US-0159233.			
PR	13-OCT-1999;	99US-0159244.			
PR	13-OCT-1999;	99US-0159255.			
PR	14-OCT-1999;	99US-0159329.			
PR	14-OCT-1999;	99US-0159330.			
PR	14-OCT-1999;	99US-0159331.			
PR	14-OCT-1999;	99US-0159637.			
PR	14-OCT-1999;	99US-0159638.			
PR	18-OCT-1999;	99US-0159584.			
PR	21-OCT-1999;	99US-0160741.			
PR	21-OCT-1999;	99US-0160767.			
PR	21-OCT-1999;	99US-0160768.			
PR	21-OCT-1999;	99US-0160770.			
PR	21-OCT-1999;	99US-0160815.			
PR	22-OCT-1999;	99US-0160980.			
PR	22-OCT-1999;	99US-0160981.			
PR	22-OCT-1999;	99US-0160989.			
PR	25-OCT-1999;	99US-0161404.			
PR	25-OCT-1999;	99US-0161405.			
PR	25-OCT-1999;	99US-0161406.			
PR	26-OCT-1999;	99US-0161359.			
PR	26-OCT-1999;	99US-0161360.			
PR	26-OCT-1999;	99US-0161361.			
PR	28-OCT-1999;	99US-0161920.			
PR	28-OCT-1999;	99US-0161922.			
PR	28-OCT-1999;	99US-0161923.			
PR	29-OCT-1999;	99US-0162142.			
Qy	13.6% Score 550.5; DB 21; Length 451;				
Best Local Similarity 31.6%; Pred. No. 4.7e-40; Mismatches 172; Indels 107; Gaps 22;					
Matches 162; Conservative 71; DR: 2001-611435/70.					
Qy	10 TLYDKVLOAHVYDBKL--DTGYVLYIDRHLVHEVTSPOAFEGL--RMAAGKVR--RPDC	62			
Db	2 TMTEKIL-ARASEKSLSVVPGDNIWVNVDLMTDVCGFAF-GIFKREFEGKAKWVDPK 59				
Qy	63 TLATTDDHNPVPTSRKALKDIASTFIKEDDSRTOCVTLEENVKEF---GVTYFGISDRKQG	118			
Qy	119 IYVIGPQQGFTLPGTTVVCGDSTSHTGAGFALAFGIGTSEVEHVLATQCLITKRSKM	178			
Db	112 VCHVALAQEGHCRPGEVILGTDHTCTAGQFATGQNTDAGVLFQGKILLJKVPPM	171			
Qy	179 RIQVGDGLAPGVSSKQDVLHAIQHIGTAGGTGAVIEFCSSVIRSLMEARMSICNMSIEG	238			
Db	172 RFILDGEMPSYQLAKDILQIIGEISVAGATYKMEFSGTIESLSMSPRMTLCNMVVA	231			
Qy	239 GARAGMVADEPDTIPEYLK-----GRPLAPKYDSEPEWKAHQYWNKLQSDPGAKY	287			
Db	232 GGKNGVIPPDDATTLYNVEACILSCLNRTSVPFEPVY-----SDGNAStP	275			

Query relates to antisense inhibitors of genes essential to prokaryotic cellular proliferation, their use in identifying the genes themselves and the encoded proteins. The prokaryotes used are Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella pneumoniae, Pseudomonas aeruginosa and Enterococcus faecalis. The invention is also useful for the identification of potential new targets for antibiotic development. The antisense nucleic acids can also be used to identify proteins used in proliferation, to express these proteins, and to obtain antibodies capable of binding to the expressed proteins. The proteins can be used to screen compounds in rational drug discovery programs. The antisense nucleic acid sequence is also useful to screen for homologous nucleic acids which are required for cell proliferation in a wide variety of organisms. The present sequence represents an

Example 3: Seq ID No 11900; 511pp; English.

WPI: 2001-611435/70.

DR: AAS54166.

XX

New polynucleotides for the identification and development of antibiotics, comprising sequences of antisense nucleic acids -

CC

PT

antibiotics, comprising sequences of antisense nucleic acids -

CC

OS

Pseudomonas aeruginosa.

XX

PN WO200170555-A2.

XX

PD 27-SEP-2001.

XX

PP 21-MAR-2001; 20001WO-US091180.

XX

PR 21-MAR-2000; 20000US-191078P.

PR 23-MAY-2000; 20000US-206848P.

PR 26-MAY-2000; 20000US-207727P.

PR 23-OCT-2000; 20000US-242578P.

PR 27-NOV-2000; 20000US-153655P.

PR 22-DEC-2000; 20000US-257931P.

PR 16-FEB-2001; 2001US-269308P.

XX

(ELIT-) ELITRA PHARM INC.

XX

PI Haselbeck R, Ohlsen KL, Zyskind JW, Wall D, Trawick JD, Carr GU;

PI Yamamoto RT, Xu HH;

XX

WPI: 2001-611435/70.

DR: AAS54166.

XX

The invention relates to antisense inhibitors of genes essential to

CC

prokaryotic cellular proliferation, their use in identifying the

CC

genes, their use in the discovery of novel antibiotics, the essential

CC

genes themselves and the encoded proteins. The prokaryotes used are

CC

Escherichia coli, Staphylococcus aureus, Salmonella typhi, Klebsiella

CC

CC essential prokaryotic cellular proliferation protein.

CC Note: The sequence data for this patent did not form part
CC of the printed specification, but was obtained in electronic
CC format directly from WIPO at
CC ftp://wipo.int/pub/published_pct_sequences.

CC XX

CC Sequence 212 AA:

Query Match 13.4%; Score 542; DB 22; Length 212;
Best Local Similarity 53.3%; Pred. No. 8e-40;
Matches 112; Conservative 34; Mismatches 50; Indels 14; Gaps 6;
QY 543 FPIILKGIAAPLEKANVDTAIIIPKQFKEKTKRTGGLGNALFYENRF--NEDGETKS--- 595
Db 4 YTQTTGLIVAPLDRANVDTDQIIPKQFLKSIKRTGFFPMLFDEWRYLDVGQPGODNSKRPL 63
QY 596 --DFVUNKEPKRKAStLWCTGANFGCSSLREHAPWALNDPGRSVIARSFAITFFNNSSFK 653
Db 64 NPDFVILNQPRYOGASVLL-ENFGCGSSREHAPWALDYGFRTVIAPSYADIFFNNSSFK 122
QY 654 NGMUPPIKIDQAQIEAI--AABARAGKEIEVDPNQIKNATGETCTFEVEBFRKIGLV 711
Db 123 NGLLI-IPEPEAEVDLFRQVEANEGYVQLSIDLAQTVTRPDGK-VLGFEVDPPRKIGLL 180
QY 712 NGLDDIGLTMOMEDKIAFEAKMTRTPWL 741
Db 181 NGLDDIGLTDADAIRAFEDGYRQQOPWL 210

Search completed: March 17, 2003, 08:49:07

Job time : 53 secs

